<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Inherit. Metab. Dis</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1573-2665</journal-id>
<journal-id journal-id-type="publisher-id">JIMD</journal-id>
<journal-title-group>
<journal-title>Journal of Inherited Metabolic Disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0141-8955</issn>
<issn pub-type="epub">1573-2665</issn>
<publisher>
<publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
<publisher-loc>Hoboken, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31268178</article-id>
<article-id pub-id-type="pmc">7250134</article-id>
<article-id pub-id-type="doi">10.1002/jimd.12146</article-id>
<article-id pub-id-type="publisher-id">JIMD12146</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropsychological attributes of urea cycle disorders: A systematic review of the literature</article-title>
<alt-title alt-title-type="left-running-head">Waisbren et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="jimd12146-cr-0001">
<name>
<surname>Waisbren</surname>
<given-names>Susan E.</given-names>
</name>
<xref ref-type="aff" rid="jimd12146-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="jimd12146-aff-0002">
<sup>2</sup>
</xref>
<address>
<email>susan.waisbren@childrens.harvard.edu</email>
</address>
</contrib>
<contrib contrib-type="author" id="jimd12146-cr-0002">
<name>
<surname>Stefanatos</surname>
<given-names>Arianna K.</given-names>
</name>
<xref ref-type="aff" rid="jimd12146-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="jimd12146-cr-0003">
<name>
<surname>Kok</surname>
<given-names>Teresa M. Y.</given-names>
</name>
<xref ref-type="aff" rid="jimd12146-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="jimd12146-cr-0004">
<name>
<surname>Ozturk‐Hismi</surname>
<given-names>Burcu</given-names>
</name>
<xref ref-type="aff" rid="jimd12146-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="jimd12146-aff-0005">
<sup>5</sup>
</xref>
</contrib>
</contrib-group>
<aff id="jimd12146-aff-0001">
<label><sup>1</sup></label>
<institution>Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
</aff>
<aff id="jimd12146-aff-0002">
<label><sup>2</sup></label>
<institution>Department of Medicine, Harvard Medical School</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
</aff>
<aff id="jimd12146-aff-0003">
<label><sup>3</sup></label>
<institution>Department of Child &amp; Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
</aff>
<aff id="jimd12146-aff-0004">
<label><sup>4</sup></label>
<institution>Horizon Therapeutics Plc</institution>
<city>Lake Forest</city>
<named-content content-type="country-part">Illinois</named-content>
</aff>
<aff id="jimd12146-aff-0005">
<label><sup>5</sup></label>
<institution>Tepecik Education and Research Hospital</institution>
<city>Izmir</city>
<country country="TR">Turkey</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Susan E. Waisbren, Metabolism Program, Boston Children's Hospital, 1 Autumn Street #525, Boston, MA 02115.<break></break>
Email: <email>susan.waisbren@childrens.harvard.edu</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2019</year>
</pub-date>
<volume>42</volume>
<issue>6</issue>
<issue-id pub-id-type="doi">10.1002/jimd.v42.6</issue-id>
<fpage>1176</fpage>
<lpage>1191</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 SSIEM <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>Journal of Inherited Metabolic Disease</italic> published by John Wiley &amp; Sons Ltd on behalf of SSIEM</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:JIMD-42-1176.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>Urea cycle disorders (UCDs) are rare inherited metabolic conditions that impair the effectiveness of the urea cycle responsible for removing excess ammonia from the body. The estimated incidence of UCDs is 1:35 000 births, or approximately 113 new patients with UCD per year. This review summarizes neuropsychological outcomes among patients with the eight UCDs in reports published since 1980. Rates of intellectual disabilities published before (and including) 2000 and after 2000 were pooled and compared for each UCD. Since diagnoses for UCDs tended to occur earlier and better treatments became more readily available after the turn of the century, this assessment will characterize the extent that current management strategies have improved neuropsychological outcomes. The pooled sample included data on cognitive abilities of 1649 individuals reported in 58 citations. A total of 556 patients (34%) functioned in the range of intellectual disabilities. The decline in the proportion of intellectual disabilities in six disorders, ranged from 7% to 41%. Results from various studies differed and the cohorts varied with respect to age at symptom onset, age at diagnosis and treatment initiation, current age, severity of the metabolic deficiency, management strategies, and ethnic origins. The proportion of cases with intellectual disabilities ranged from 9% to 65% after 2000 in the seven UCDs associated with cognitive deficits. Positive outcomes from some studies suggest that it is possible to prevent or reverse the adverse impact of UCDs on neuropsychological functioning. It is time to “raise the bar” in terms of expectations for treatment effectiveness.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="jimd12146-kwd-0001">intellectual disabilities</kwd>
<kwd id="jimd12146-kwd-0002">neuropsychological outcomes</kwd>
<kwd id="jimd12146-kwd-0003">urea cycle disorders</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-0001">
<funding-source>
<institution-wrap>
<institution>Türkiye Bilimsel ve Teknolojik Araştirma Kurumu </institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100004410</institution-id>
</institution-wrap>
</funding-source>
<award-id>TUBITAK‐1059B191601447</award-id>
</award-group>
<award-group id="funding-0002">
<funding-source>Urea Cycle Disorders Consortium</funding-source>
<award-id>U54HD061221</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="1"></table-count>
<page-count count="16"></page-count>
<word-count count="12457"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>November 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.2 mode:remove_FC converted:26.05.2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="jimd12146-cit-9001" publication-type="journal">
<string-name>
<surname>Waisbren</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Stefanatos</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Kok</surname>
<given-names>TMY</given-names>
</string-name>, <string-name>
<surname>Ozturk‐Hismi</surname>
<given-names>B</given-names>
</string-name>. <article-title>Neuropsychological attributes of urea cycle disorders: A systematic review of the literature</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2019</year>;<volume>42</volume>:<fpage>1176</fpage>–<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1002/jimd.12146</pub-id>
<pub-id pub-id-type="pmid">31268178</pub-id></mixed-citation>
</p>
<fn-group id="jimd12146-ntgp-1001">
<fn id="jimd12146-note-1001">
<p>
<bold>Communicating Editor:</bold> Peter Burgard</p>
</fn>
<fn id="jimd12146-note-1002">
<p>
<bold>Funding information</bold> Türkiye Bilimsel ve Teknolojik Araştirma Kurumu, Grant/Award Number: TUBITAK‐1059B191601447; Urea Cycle Disorders Consortium, Grant/Award Number: U54HD061221</p>
</fn>
</fn-group>
</notes>
</front>
<body id="jimd12146-body-0001">
<def-list id="jimd12146-lp-0001" list-content="abbreviations">
<title>Abbreviations</title>
<def-item>
<term id="jimd12146-li-0001">ARGD</term>
<def id="jimd12146-li-0002">
<p>arginase deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0003">ASLD/ALD</term>
<def id="jimd12146-li-0004">
<p>argininosuccinate lyase deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0005">ASSD/ASD</term>
<def id="jimd12146-li-0006">
<p>argininosuccinate synthetase deficiency; citrullinemia type I</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0007">CI</term>
<def id="jimd12146-li-0008">
<p>confidence interval</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0009">CPS1</term>
<def id="jimd12146-li-0010">
<p>carbamoyl phosphate synthetase 1</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0011">CPS1D</term>
<def id="jimd12146-li-0012">
<p>carbamoyl phosphate synthetase 1 deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0013">CTLN2</term>
<def id="jimd12146-li-0014">
<p>citrullinemia type II</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0015">DQ</term>
<def id="jimd12146-li-0016">
<p>developmental quotient</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0017">FTTDCD</term>
<def id="jimd12146-li-0018">
<p>failure to thrive and dyslipidemia caused by citrin deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0019">HA</term>
<def id="jimd12146-li-0020">
<p>hyperammonemia</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0021">HHH</term>
<def id="jimd12146-li-0022">
<p>hyperornithinemia‐hyperammonemia‐homocitrullinuria;</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0023">ID</term>
<def id="jimd12146-li-0024">
<p>intellectual disability</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0025">IQ</term>
<def id="jimd12146-li-0026">
<p>intelligence quotient</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0027">NAG</term>
<def id="jimd12146-li-0028">
<p>
<italic>N</italic>‐acetylglutamate</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0029">NAGSD</term>
<def id="jimd12146-li-0030">
<p>
<italic>N</italic>‐acetylglutamate synthase deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0031">NBS</term>
<def id="jimd12146-li-0032">
<p>newborn screening</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0033">NCG</term>
<def id="jimd12146-li-0034">
<p>
<italic>N</italic>‐carbamylglutamate</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0035">NICCD</term>
<def id="jimd12146-li-0036">
<p>neonatal intrahepatic cholestasis caused by citrin deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0037">OR</term>
<def id="jimd12146-li-0038">
<p>odds ratio</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0039">ORNT1</term>
<def id="jimd12146-li-0040">
<p>mitochondrial ornithine transporter</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0041">ORNT1D</term>
<def id="jimd12146-li-0042">
<p>mitochondrial ornithine transporter 1 deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0043">OTCD</term>
<def id="jimd12146-li-0044">
<p>ornithine transcarbamylase deficiency</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0045">RUSP</term>
<def id="jimd12146-li-0046">
<p>recommended Uniform Screening Panel</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0047">SD</term>
<def id="jimd12146-li-0048">
<p>standard deviation</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0049">UCD</term>
<def id="jimd12146-li-0050">
<p>urea cycle disorder</p>
</def>
</def-item>
<def-item>
<term id="jimd12146-li-0051">UCDC</term>
<def id="jimd12146-li-0052">
<p>Urea Cycle Disorders Consortium</p>
</def>
</def-item>
</def-list>
<sec id="jimd12146-sec-0001">
<label>1</label>
<title>INTRODUCTION</title>
<p>Urea cycle disorders (UCDs) are a set of rare inherited metabolic conditions that result in defects in urea cycle proteins responsible for removing excess ammonia from the body.<xref ref-type="ref" rid="jimd12146-bib-0001">1</xref> The estimated overall incidence of UCDs in the United States and parts of Europe is 1:35 000 births, or approximately 113 new patients with UCD per year.<xref ref-type="ref" rid="jimd12146-bib-0002">2</xref>
</p>
<p>Eight UCDs have been identified, each associated with defects in one of the six enzymes or two transporters of the urea cycle (Figure <xref ref-type="fig" rid="jimd12146-fig-0001">1</xref>). The UCDs caused by enzyme deficiencies include proximal disorders, associated with altered or inhibited functioning of the mitochondrial enzymes: <italic>N</italic>‐acetylglutamate synthase (NAGS) deficiency (NAGSD; OMIM #237310), carbamoyl phosphate synthetase 1 (CPS1) deficiency (CPS1D; OMIM #237300), and ornithine transcarbamylase (OTC) deficiency (OTCD; OMIM #311250). The distal disorders, associated with altered functioning of the cytosolic enzymes, are argininosuccinate synthetase (ASS) deficiency /citrullinemia type I (ASSD; OMIM #215700), argininosuccinate lyase (ASL) deficiency (ASLD; ALD)/argininosuccinic aciduria (ASA; OMIM #207900), and arginase (ARG) deficiency/argininemia (ARGD; OMIM #207800). Defects in two mitochondrial transporters also lead to UCD: citrin deficiency (mitochondrial aspartate/glutamate carrier deficiency; OMIM #605814) and mitochondrial ornithine transporter 1 (ORNT1) deficiency (ORNT1D), also referred to as hyperornithinemia‐hyperammonemia‐homocitrullinuria (HHH) syndrome (OMIM #238970). Disruption of the urea cycle leads to insufficient detoxification of ammonia to urea and a subsequent buildup of ammonia in the brain and other tissues. Consequently, ammonia accumulation or increases in glutamine resulting from hyperammonemia (HA) lead to astrocyte swelling and cytotoxic brain edema.<xref ref-type="ref" rid="jimd12146-bib-0003">3</xref>
</p>
<fig fig-type="Figure" id="jimd12146-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>The urea cycle. Abbreviations: ARG1, arginase 1; ASL, argininosuccinate lyase; ASS, argininosuccinate synthetase; CPSI, carbamoyl phosphate synthetase 1; NAGS, <italic>N</italic>‐acetylglutamate synthase; OTC, ornithine transcarbamylase; ORNT1, mitochondrial ornithine transporter 1</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="JIMD-42-1176-g001"></graphic>
</fig>
<p>Apart from X‐linked OTCD, inheritance of all UCDs is autosomal recessive. Acute management of HA consists of renal replacement therapies to rapidly decrease blood ammonia levels, intravenous nitrogen scavenger drugs (sodium benzoate, alone or in combination with sodium phenylacetate, arginine),<xref ref-type="ref" rid="jimd12146-bib-0004">4</xref> hydration, protein restriction, and treating catabolism with adequate calories from glucose, fats, and essential amino acids.<xref ref-type="ref" rid="jimd12146-bib-0001">1</xref>, <xref ref-type="ref" rid="jimd12146-bib-0005">5</xref> Long‐term management includes dietary treatment (protein restriction in combination with essential amino acids, vitamin, and mineral supplementation) and replacement of arginine and citrulline, if indicated. For UCDs other than NAGSD, ammonia/nitrogen scavenger drugs (sodium benzoate, sodium phenylbutyrate, and glycerol phenylbutyrate) are used to control ammonia levels.<xref ref-type="ref" rid="jimd12146-bib-0005">5</xref>, <xref ref-type="ref" rid="jimd12146-bib-0006">6</xref>
<italic>N</italic>‐carbamylglutamate is a CPS1 activator that is used to replace NAGS in patients with NAGSD (and some with CPS1D). Liver transplantation is a reasonable long‐term management option for individuals with a UCD other than NAGSD.<xref ref-type="ref" rid="jimd12146-bib-0005">5</xref>, <xref ref-type="ref" rid="jimd12146-bib-0006">6</xref>, <xref ref-type="ref" rid="jimd12146-bib-0007">7</xref>, <xref ref-type="ref" rid="jimd12146-bib-0008">8</xref>
</p>
<p>This article presents a review of published studies with a focus on whether improvements in treatment have been successful in the prevention of intellectual disabilities in patients with UCDs. Since diagnoses tended to occur earlier and better treatments became more readily available after the turn of the century,<xref ref-type="ref" rid="jimd12146-bib-0004">4</xref>, <xref ref-type="ref" rid="jimd12146-bib-0009">9</xref> assessment results of cognitive functioning from studies published before and including the year 2000 (≤2000) and after the year 2000 (&gt;2000) were compared for each UCD.</p>
</sec>
<sec id="jimd12146-sec-0002">
<label>2</label>
<title>METHODS</title>
<p>The PubMed database was searched for articles reporting neuropsychological outcomes in patients with UCDs through July 1, 2018, using the search terms “urea cycle disorder” and the various names for the eight disorders. Bibliographies identified additional relevant articles. Only articles published after 1980 were included, since that was about the time ammonia scavenger drugs were first introduced.<xref ref-type="ref" rid="jimd12146-bib-0010">10</xref> Variables considered were measures of cognitive functioning (eg, developmental quotients [DQ] and intelligence quotient [IQ]), age of symptom onset, age of diagnosis, treatment, and biomarkers. Age of symptom onset was defined as “early onset” (if HA or other symptoms occurred before 30 days of age) or “late onset” (if occurring at or after 30 days of age). When a case report or series of cases were updated, only the most recent publication was used. In total, 58 studies were used in the analyses presented in Table <xref ref-type="table" rid="jimd12146-tbl-0001">1</xref>. Table <xref ref-type="supplementary-material" rid="jimd12146-supitem-0001">S1</xref>a‐g presents data from studies used in the pooled results (some of which were not described in the text). The data are described in detail and respective studies, along with the additional references, are included in the Supplementary Table <xref ref-type="supplementary-material" rid="jimd12146-supitem-0001">S1</xref>. Additional studies were referenced in the text, but excluded from the table if they provided information on behavioral or psychiatric issues. Pooled data for each disorder included the number of cases in the series, the number receiving a neuropsychological evaluation and/or description of cognitive functioning, and the number and percent with intellectual disabilities, defined as a DQ or IQ equal to or more than two SDs below the normative mean. Developmental tests and intelligence tests used in each study usually reported scores based on a normative mean of 100 with an SD of 15, as in the Wechsler IQ tests. Thus, intellectual disabilities were noted if the IQ/DQ was ≤70 on the Bayley Scales of Infant and Toddler Development or any of the Wechsler IQ tests. Less common were scores based on a normative mean of 50 ± 10 or z‐scores. The studies related to each disorder were pooled according to the year of publication unless the data collection time was recorded. For each disorder separately, odds ratios for intellectual deficiencies &gt;2000 compared to ≤2000 were calculated along with 95% confidence intervals (CI) and <italic>P</italic>‐values using Fisher's exact test. We present descriptive statistics combining proximal disorders compared with distal disorders, but do not focus on these results, since outcomes vary among the different disorders.</p>
<table-wrap id="jimd12146-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Summary of Cognitive Outcomes in Urea Cycle Disorders comparing published results before and including the year 2000 and after the year 2000</p>
</caption>
<table frame="hsides" rules="cols">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<tbody valign="top">
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">
<bold>Proximal disorders</bold>
</td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Carbamoyl phosphate synthetase 1 (CPS1) deficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>neonatal</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>late</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>neonatal ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>late ID</sub>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">51</td>
<td align="left" colspan="1" rowspan="1" valign="top">17</td>
<td align="left" colspan="1" rowspan="1" valign="top">11</td>
<td align="left" colspan="1" rowspan="1" valign="top">65%</td>
<td align="left" colspan="1" rowspan="1" valign="top">14</td>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
<td align="left" colspan="1" rowspan="1" valign="top">9 (64%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">2 (67%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">76</td>
<td align="left" colspan="1" rowspan="1" valign="top">52</td>
<td align="left" colspan="1" rowspan="1" valign="top">21</td>
<td align="left" colspan="1" rowspan="1" valign="top">40%</td>
<td align="left" colspan="1" rowspan="1" valign="top">33</td>
<td align="left" colspan="1" rowspan="1" valign="top">18</td>
<td align="left" colspan="1" rowspan="1" valign="top">12 (36%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">10 (56%)</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0.38 (0.098, 1.311)</p>
<p>
<italic>P</italic> = 0.10</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0.33</p>
<p>(0.068, 1.383) <italic>P</italic> = 0.11</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0.64 (0.009, 14.443)</p>
<p>
<italic>P</italic> = 1</p>
</td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">
<italic>N</italic>‐acetylglutamate synthase (NAGS) deficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">10</td>
<td align="left" colspan="1" rowspan="1" valign="top">10</td>
<td align="left" colspan="1" rowspan="1" valign="top">5</td>
<td align="left" colspan="1" rowspan="1" valign="top">50%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">37</td>
<td align="left" colspan="1" rowspan="1" valign="top">22</td>
<td align="left" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">9%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.11 (0.008, 0.903) <italic>P</italic> = 0.02</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Ornithine transcarbamylase (OTC) deficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000 Males</td>
<td align="left" colspan="1" rowspan="1" valign="top">191</td>
<td align="left" colspan="1" rowspan="1" valign="top">64</td>
<td align="left" colspan="1" rowspan="1" valign="top">15</td>
<td align="left" colspan="1" rowspan="1" valign="top">23%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000 Males</td>
<td align="left" colspan="1" rowspan="1" valign="top">153</td>
<td align="left" colspan="1" rowspan="1" valign="top">145</td>
<td align="left" colspan="1" rowspan="1" valign="top">32</td>
<td align="left" colspan="1" rowspan="1" valign="top">22%</td>
<td align="left" colspan="4" rowspan="1" valign="top">Excludes cases from Rüegger et al which did not specify how many males and females had ID</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0.93 (0.440, 2.013)</p>
<p>
<italic>P</italic> = 0.86</p>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000 Females</td>
<td align="left" colspan="1" rowspan="1" valign="top">177</td>
<td align="left" colspan="1" rowspan="1" valign="top">115</td>
<td align="left" colspan="1" rowspan="1" valign="top">47</td>
<td align="left" colspan="1" rowspan="1" valign="top">41%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000 Females</td>
<td align="left" colspan="1" rowspan="1" valign="top">404</td>
<td align="left" colspan="1" rowspan="1" valign="top">403</td>
<td align="left" colspan="1" rowspan="1" valign="top">59</td>
<td align="left" colspan="1" rowspan="1" valign="top">15%</td>
<td align="left" colspan="4" rowspan="1" valign="top">Excludes cases from Rüegger et al which did not specify how many males and females had ID</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0.25 (0.152, 0.406)</p>
<p>
<italic>P</italic> &lt; 0.001</p>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>≤2000</p>
<p>All cases</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">368</td>
<td align="left" colspan="1" rowspan="1" valign="top">179</td>
<td align="left" colspan="1" rowspan="1" valign="top">62</td>
<td align="left" colspan="1" rowspan="1" valign="top">35%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>&gt;2000</p>
<p>All cases</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">675</td>
<td align="left" colspan="1" rowspan="1" valign="top">666</td>
<td align="left" colspan="1" rowspan="1" valign="top">128</td>
<td align="left" colspan="1" rowspan="1" valign="top">19%</td>
<td align="left" colspan="4" rowspan="1" valign="top">Includes cases from Rüegger et al which was excluded from the numbers reported for males and females separately above. Because of this, the sum of males and females reported for all cases (&gt;2000) is less than the number reported here for all cases.</td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.45 (0.308, 0.659) <italic>P</italic> &lt; 0.001</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">All proximal disorders</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">429</td>
<td align="left" colspan="1" rowspan="1" valign="top">206</td>
<td align="left" colspan="1" rowspan="1" valign="top">78</td>
<td align="left" colspan="1" rowspan="1" valign="top">37%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">788</td>
<td align="left" colspan="1" rowspan="1" valign="top">740</td>
<td align="left" colspan="1" rowspan="1" valign="top">151</td>
<td align="left" colspan="1" rowspan="1" valign="top">20%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.42 (0.298,0.597) <italic>P</italic> &lt; 0.001</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">
<bold>Distal disorders</bold>
</td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Argininosuccinate synthetase (ASS) deficiency/citrullinemia type I</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">88</td>
<td align="left" colspan="1" rowspan="1" valign="top">50</td>
<td align="left" colspan="1" rowspan="1" valign="top">34</td>
<td align="left" colspan="1" rowspan="1" valign="top">68%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">156</td>
<td align="left" colspan="1" rowspan="1" valign="top">137</td>
<td align="left" colspan="1" rowspan="1" valign="top">51</td>
<td align="left" colspan="1" rowspan="1" valign="top">37%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.28 (0.131, 0.583) <italic>P</italic> &lt; 0.001</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Argininosuccinate lyase deficiency (ASLD; ALD)/Argininosuccinic aciduria (ASA)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">67</td>
<td align="left" colspan="1" rowspan="1" valign="top">42</td>
<td align="left" colspan="1" rowspan="1" valign="top">23</td>
<td align="left" colspan="1" rowspan="1" valign="top">55%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">232</td>
<td align="left" colspan="1" rowspan="1" valign="top">212</td>
<td align="left" colspan="1" rowspan="1" valign="top">131</td>
<td align="left" colspan="1" rowspan="1" valign="top">62%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>Odds ratio*** (95% CI)</p>
<p>
<italic>P</italic>‐value</p>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">1.33 (0.644, 2.743) <italic>P</italic> = 0.39</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Arginase (ARG) deficiency / Argininemia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">8</td>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">28</td>
<td align="left" colspan="1" rowspan="1" valign="top">24</td>
<td align="left" colspan="1" rowspan="1" valign="top">15</td>
<td align="left" colspan="1" rowspan="1" valign="top">63%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0 (0, 3.153)</p>
<p>
<italic>P</italic> = 0.27</p>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">All distal disorders</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">163</td>
<td align="left" colspan="1" rowspan="1" valign="top">96</td>
<td align="left" colspan="1" rowspan="1" valign="top">61</td>
<td align="left" colspan="1" rowspan="1" valign="top">64%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">416</td>
<td align="left" colspan="1" rowspan="1" valign="top">373</td>
<td align="left" colspan="1" rowspan="1" valign="top">197</td>
<td align="left" colspan="1" rowspan="1" valign="top">53%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.64 (0.392, 1.043) <italic>P</italic> = 0.07</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Mitochondrial transporter deficiencies</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% <sub>ID</sub>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Citrin deficiency (mitochondrial aspartate/glutamate carrier deficiency)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">‐‐</td>
<td align="left" colspan="4" rowspan="1" valign="top">No studies reporting cognitive outcomes were found for Citrin deficiency ≤2000.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">138</td>
<td align="left" colspan="1" rowspan="1" valign="top">137</td>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">3%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">Ornithine transporter 1 deficiency (ORNT1D); Hyperornithinemia‐hyperammonemia‐homocitrullinuria (HHH) syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">38</td>
<td align="left" colspan="1" rowspan="1" valign="top">32</td>
<td align="left" colspan="1" rowspan="1" valign="top">23</td>
<td align="left" colspan="1" rowspan="1" valign="top">72%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">85</td>
<td align="left" colspan="1" rowspan="1" valign="top">65</td>
<td align="left" colspan="1" rowspan="1" valign="top">42</td>
<td align="left" colspan="1" rowspan="1" valign="top">65%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.72 (0.249, 1.947) <italic>P</italic> = 0.50</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="9" rowspan="1" valign="top">
<bold>All disorders</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>series</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>CF</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">N <sub>ID</sub>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">% ID</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">≤2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">630</td>
<td align="left" colspan="1" rowspan="1" valign="top">334</td>
<td align="left" colspan="1" rowspan="1" valign="top">162</td>
<td align="left" colspan="1" rowspan="1" valign="top">49%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">&gt;2000</td>
<td align="left" colspan="1" rowspan="1" valign="top">1427</td>
<td align="left" colspan="1" rowspan="1" valign="top">1315</td>
<td align="left" colspan="1" rowspan="1" valign="top">394</td>
<td align="left" colspan="1" rowspan="1" valign="top">30%</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="4" rowspan="1" valign="top">Odds ratio*** (95% CI) <italic>P</italic>‐value</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<p>0.45 (0.353, 0.585)</p>
<p>
<italic>P</italic> &lt; 0.001</p>
</td>
<td align="left" colspan="4" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
<table-wrap-foot id="jimd12146-ntgp-0001">
<fn id="jimd12146-note-0001">
<p>* N<sub>series</sub>, total number of cases reported in published studies included in this review; N <sub>CF</sub>, number of cases reporting on cognitive functioning; N <sub>ID</sub>, number of cases with intellectual disabilities; % <sub>ID</sub>, percentage of cases with intellectual disabilities; N <sub>late</sub>, number of late‐onset cases reporting cognitive functioning; N <sub>late ID</sub>, number of late‐onset cases with intellectual disabilities; N <sub>neonatal</sub>, number of neonatal‐onset cases reporting cognitive functioning; N <sub>neonatal ID</sub>, number of neonatal‐onset cases with intellectual disabilities; ≤ 2000, prior to and including the year 2000; &gt; 2000, after the year 2000; CI, confidence interval.</p>
</fn>
<fn id="jimd12146-note-0002">
<p>
<sup>**</sup>The estimated odds ratios (Fisher's exact test): Comparing rates of intellectual disabilities ≤2000 to &gt;2000; 95% confidence intervals, and <italic>P</italic>‐values.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="jimd12146-sec-0004">
<label>3</label>
<title>RESULTS</title>
<sec id="jimd12146-sec-0005">
<label>3.1</label>
<title>Proximal (mitochondrial) urea cycle disorders</title>
<sec id="jimd12146-sec-0006">
<label>3.1.1</label>
<title>Carbamoyl phosphate synthetase 1 deficiency</title>
<p>CPS1D is rare, affecting approximately 1:150 000 to 1:200 000 individuals in the United States and Europe.<xref ref-type="ref" rid="jimd12146-bib-0011">11</xref> CPSID is characterized by the early or late onset form. Neonates with CPS1D experience severe HA, and many die in the newborn period.<xref ref-type="ref" rid="jimd12146-bib-0012">12</xref>, <xref ref-type="ref" rid="jimd12146-bib-0013">13</xref> Survival rates may depend on age at onset of the first HA episode, availability of nitrogen‐reducing therapies, and occurrence of HA coma.<xref ref-type="ref" rid="jimd12146-bib-0014">14</xref> Long‐term outcomes range from near‐normal functioning to severe psychiatric problems and cognitive deficits.<xref ref-type="ref" rid="jimd12146-bib-0015">15</xref>
</p>
<p>For example, among two siblings with identical genotypes for CPS1D, one died as a neonate and the other received dietary therapy and functioned normally at age 45 years.<xref ref-type="ref" rid="jimd12146-bib-0016">16</xref> Another child was rescued after fulminant neonatal‐onset but experienced severe global developmental delay.<xref ref-type="ref" rid="jimd12146-bib-0017">17</xref> Three infants died despite treatment.<xref ref-type="ref" rid="jimd12146-bib-0012">12</xref> In six infants with neonatal onset, one died and five exhibited developmental delay.<xref ref-type="ref" rid="jimd12146-bib-0018">18</xref>
</p>
<p>Rüegger et al<xref ref-type="ref" rid="jimd12146-bib-0019">19</xref> presented a series of 208 patients with “non‐classical” UCDs, defined as “…those with symptom onset after the newborn period; a mild disease course; uncommon presentations (at any age); asymptomatic individuals (screened because of affected relatives or identified through newborn screening, NBS) with biochemical features of a UCD”. The two individuals with CPS1D (one child and one adult) in this series had intellectual disabilities. In contrast, there was a case report of a baby diagnosed at 1 month of age with severe HA who received hemodialysis and exhibited “good” development at age 15 months.<xref ref-type="ref" rid="jimd12146-bib-0020">20</xref> Kurokawa and colleagues reported on 18 patients who were identified because of clinical symptoms.<xref ref-type="ref" rid="jimd12146-bib-0021">21</xref> Among the 15 neonatal‐onset cases, four survived but one who had severe intellectual disabilities died later and two did not have intellectual disabilities (one of whom had liver transplantation). Among the three late‐onset cases, one died at age 31 years at the time of diagnosis, one had intellectual disabilities (diagnosed at age 45 years), and one diagnosed at age 13 years performed above that range.</p>
<p>In another series, 12 children with neonatal‐onset and 3 adults with late‐onset CPS1D were identified.<xref ref-type="ref" rid="jimd12146-bib-0022">22</xref> Among the early‐onset cases, nine died before the age of 2 years and 1 one died at the age of 4 years. Two children developed normally: one aged 3 years with liver transplantation and one aged 2 months awaiting transplantation. Two of the adults had intellectual disabilities and one had intermittent HA.</p>
<p>Outcomes varied among the 22 cases with CPS1D enrolled in the UCDC Longitudinal Study.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> The mean Bayley Cognitive Composite score (similar to a DQ) among the 10 infants receiving evaluations was 77 (SD = 17), ranging from 60 to 85. Four of the five children evaluated at preschool age demonstrated behaviors common in children with autism spectrum, but none of the nine preschool‐ or school‐aged children evaluated had an IQ &lt;71. Two adults with CPS1D performed in the range of intellectual disability (IQ of 66 and 62) and two others performed in the average range (IQ of 105 and 86).</p>
<p>Mild deficiencies lead to later or even adult‐onset CPS1D. In one study, two children with late‐onset CPS1D first exhibited signs of psychiatric disturbances, “delirium” in one case and autistic behaviors in the other, which improved with dietary treatment, although one had intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0024">24</xref> A young woman with mild learning disabilities experienced intermittent nausea, vomiting, and psychosis (excitation, aggression, and insomnia) during her menses since age 13.<xref ref-type="ref" rid="jimd12146-bib-0025">25</xref> At age 18, she presented with coma and CPS1D was finally diagnosed. She recovered from the coma but performed in the range of intellectual disabilities thereafter.</p>
<p>Another woman with CPS1D, who had a history of learning disabilities and several episodes of disorientation, was not diagnosed until experiencing a severe HA episode with coma during pregnancy.<xref ref-type="ref" rid="jimd12146-bib-0026">26</xref> Treatment led to symptom resolution and baseline functioning, although no neuropsychological testing was performed. The baby was born at 22 weeks and died.</p>
<p>Foschi et al<xref ref-type="ref" rid="jimd12146-bib-0007">7</xref> described the case of a 17‐year‐old girl who was diagnosed with CPS1D at age 3 years. Before liver transplantation, she had intermittent attacks characterized by somnolence, ataxia, coordination defects, and temporal cognition distortion. Following liver transplantation, she led a normal life, with good clinical condition and no dietary restrictions or hospitalizations.</p>
<p>Another case report described a 49‐year‐old man with late‐onset CPS1D who experienced a stroke and HA encephalopathy.<xref ref-type="ref" rid="jimd12146-bib-0027">27</xref> The HA episodes resolved with liver transplantation, and the patient was able to return to work.</p>
<p>According to studies published ≤2000 with data on cognitive functioning, 65% of surviving patients with CPS1D had intellectual disability, and the prevalence of intellectual disabilities was 64% and 67% among neonatal‐onset and later‐onset individuals, respectively. The rate of intellectual disability for children would have been much higher, yet at least one‐third of early‐onset children died in infancy or shortly thereafter with neurological symptoms. The prevalence of intellectual disabilities declined after 2000 in both neonatal‐ and late‐onset patients (36% and 56%, respectively).</p>
</sec>
<sec id="jimd12146-sec-0007">
<label>3.1.2</label>
<title>
<italic>N</italic>‐acetylglutamate synthase deficiency (NAGSD)</title>
<p>A defect in the next step of the urea cycle leads to NAGSD—the rarest of the UCDs—with an estimated incidence of less than 1:2 000 000 in the United States and Europe.<xref ref-type="ref" rid="jimd12146-bib-0002">2</xref> NAG is synthesized by the mitochondrial enzyme NAGS and activates CPS1. Without NAGS, there is no activity of CPS1 and, hence, clinical and biochemical features of NAGSD are indistinguishable from CPS1D, with increased plasma ammonia and glutamine, decreased plasma citrulline, and normal to low levels of urinary orotic acid. Adult patients are rare and seldom recognized. Symptoms include a self‐selected low‐protein diet, headaches, vomiting, lethargy, behavioral changes, confusion, altered consciousness, combativeness, and encephalopathy.<xref ref-type="ref" rid="jimd12146-bib-0028">28</xref> Treatment with <italic>N</italic>‐carbamylglutamate has been recommended as the treatment of choice for NAGSD, allowing for an unrestricted diet and no other medications except during a metabolic crisis.<xref ref-type="ref" rid="jimd12146-bib-0029">29</xref>
</p>
<p>Bachmann et al reported on the first two cases of NAGSD, both of whom died in infancy with severe neuropathy associated with HA.<xref ref-type="ref" rid="jimd12146-bib-0030">30</xref> Another case report described early‐onset symptoms and severe intellectual disability and motor delay; the child died at the age of 9 years.<xref ref-type="ref" rid="jimd12146-bib-0031">31</xref> Pandya et al reported on two brothers, one of whom appeared normal at 18 months and the other who exhibited developmental delays at 6 months.<xref ref-type="ref" rid="jimd12146-bib-0032">32</xref> The next published case presented at age 2 months and experienced severe intellectual disability and cortical blindness by age 2 years despite treatment.<xref ref-type="ref" rid="jimd12146-bib-0033">33</xref> Other early cases represented a mixed set of outcomes.<xref ref-type="ref" rid="jimd12146-bib-0032">32</xref>, <xref ref-type="ref" rid="jimd12146-bib-0034">34</xref>, <xref ref-type="ref" rid="jimd12146-bib-0035">35</xref>, <xref ref-type="ref" rid="jimd12146-bib-0036">36</xref>, <xref ref-type="ref" rid="jimd12146-bib-0037">37</xref>, <xref ref-type="ref" rid="jimd12146-bib-0038">38</xref>, <xref ref-type="ref" rid="jimd12146-bib-0039">39</xref>
</p>
<p>Later reports suggested a positive impact with prompt diagnoses via genetic testing and treatment initiation.<xref ref-type="ref" rid="jimd12146-bib-0040">40</xref>, <xref ref-type="ref" rid="jimd12146-bib-0041">41</xref>, <xref ref-type="ref" rid="jimd12146-bib-0042">42</xref>
</p>
<p>Sancho‐Vaello et al<xref ref-type="ref" rid="jimd12146-bib-0043">43</xref> reviewed genetic mutations in published and unpublished cases (56 patients from 42 families). In this series, there were 17 previously unpublished cases with outcome data. Among the 10 patients with neonatal‐onset disease, six died within 20 days, three had a normal outcome, and one had developmental delay even with treatment. Of the seven late‐onset cases, one died without treatment and six had a normal outcome.</p>
<p>All four participants with NAGSD (one child and three adults) in the UCDC Longitudinal Study performed within the average range of intellectual functioning (IQ of 87‐116).<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> One woman who was undiagnosed until adulthood experienced serious psychiatric problems and cognitive impairment before her diagnosis and treatment for NAGSD.</p>
<p>Pooled data of the 10 cases reported ≤2000 revealed intellectual disabilities in five (50%). Two of the 22 cases (9%) described after 2000 experienced intellectual disabilities, although neonatal death continued to be a common occurrence.</p>
</sec>
<sec id="jimd12146-sec-0008">
<label>3.1.3</label>
<title>Ornithine transcarbamylase deficiency</title>
<p>OTCD is the most common type of UCD, affecting approximately 1:56500 individuals.<xref ref-type="ref" rid="jimd12146-bib-0002">2</xref> Clinical severity is variable. As inheritance of OTCD is X‐linked, the degree of enzyme deficiency and neuropsychological impairment often differs between males and females, with females being less affected or asymptomatic. Infant boys often present with life‐threatening HA within the first hours of life, and nearly half do not survive.<xref ref-type="ref" rid="jimd12146-bib-0044">44</xref> Thus, studies reporting on neuropsychological outcomes in OTCD are inherently biased by the exclusion of the most severely affected male patients.</p>
<p>Msall and colleagues reported that two of five (40%) male patients with OTCD had intellectual disabilities (IQ &lt;70) with a mean IQ of 56 (SD = 18).<xref ref-type="ref" rid="jimd12146-bib-0045">45</xref> An additional two male patients with severe neurological involvement died before age 1 year. Among heterozygous females with OTCD, intellectual disabilities were found in five of 13 (38%) in one study<xref ref-type="ref" rid="jimd12146-bib-0046">46</xref> and in five of 10 (50%) in another study (mean IQ = 61; SD = 66).<xref ref-type="ref" rid="jimd12146-bib-0047">47</xref>
</p>
<p>Uchino et al<xref ref-type="ref" rid="jimd12146-bib-0048">48</xref> reported outcome data for 140 patients with OTCD. The 5‐year survival rate was 30% for males and 39% for females. Among patients who survived 5 years after symptom onset, 3 of 27 (11%) males and 5 of 19 (26%) females had intellectual disabilities. All patients whose highest recorded ammonia concentration was &lt;180 μmol/L were neurologically intact, whereas all patients whose peak ammonia concentration was &gt;350 μmol/L sustained severe brain damage or died.</p>
<p>Nassogne et al<xref ref-type="ref" rid="jimd12146-bib-0049">49</xref> summarized outcomes in 150 individuals identified with OTCD from 1972 to 2000. All but one of the 66 boys with neonatal‐onset OTCD died. Chronic psychiatric problems were the predominant symptom before diagnosis in 4 of the 46 late‐onset boys and 2 of the 36 late‐onset girls. Agitation, confusion, aggression, and irritability were often noted. Of the surviving boys, nearly one‐half had “moderate” difficulties, whereas 20% of the surviving girls were described as being severely affected.</p>
<p>Another series included long‐term outcomes of 28 surviving children (boys, n = 5; girls, n = 23) assessed at one clinic.<xref ref-type="ref" rid="jimd12146-bib-0050">50</xref> This sample included 4 neonatal‐onset (boys, n = 1; girls, n = 3) and 20 late‐onset cases (boys, n = 3; girls, n = 17). Overall, 50% of individuals performed in the range of intellectual disabilities (boys, n = 1; girls, n = 13).</p>
<p>In the Bachmann et al<xref ref-type="ref" rid="jimd12146-bib-0051">51</xref> sample that included 36 individuals with OTCD, all those with an initial ammonia level &gt; 300 μmol/L or a maximum ammonia level &gt; 480 μmol/L had intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0051">51</xref> Krivitzky et al<xref ref-type="ref" rid="jimd12146-bib-0052">52</xref> reported intellectual disabilities in 20% of individuals with OTCD participating in the UCDC Longitudinal Study. An updated report from the UCDC presented data on different age cohorts.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> Infant girls (n = 25) had a mean Bayley Cognitive Composite score of 96 (SD = 16) and 13% had a DQ &lt;71. In contrast, infant boys (n = 27) had a mean DQ of 74 (SD = 19) and 52% had a DQ &lt;71. The preschool cohort of 31 girls with OTCD performed well, with a mean Full Scale IQ of 105 (SD = 15), and none performed in the range of intellectual disabilities. The 15 preschool age boys in this cohort attained a mean Full Scale IQ of 91 (SD = 22) and 13% had an IQ &lt;71. By school age (6‐16 years), 8% of the 97 girls and 9% of the 34 boys with OTCD had an IQ &lt;71. The adult OTCD cohort comprised 156 women and 25 men. The women attained a mean Full Scale IQ of 102 (SD = 16) and 5% had an IQ &lt;71, while the men attained a mean Full Scale IQ of 101 (SD = 21) and 15% had an IQ &lt;71.</p>
<p>In the Rüegger et al<xref ref-type="ref" rid="jimd12146-bib-0019">19</xref> study of individuals with “non‐classical” UCDs, intellectual disabilities were identified in 37 of 121 individuals (31%) with OTCD. Overall, 64% of the 83 females and 71% of the 38 males in the sample had experienced ≥1 HA episode, a far greater percentage than those with intellectual disabilities, suggesting that HA alone does not necessarily lead to severe long‐term cognitive effects.</p>
<p>Martín‐Hernández et al<xref ref-type="ref" rid="jimd12146-bib-0053">53</xref> summarized registry data from 26 males and 41 females. Although neuropsychological assessments were not completed for most patients, 45% exhibited signs of neurologic damage (males, n = 7; females, n = 22). Other studies showed poor executive functioning, working memory, fine motor abilities, and academic achievement.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref>, <xref ref-type="ref" rid="jimd12146-bib-0054">54</xref>
</p>
<p>Several studies suggest that intellectual abilities may not be affected if ammonia levels do not reach toxic levels (generally defined as &gt;100 μmol/L). In a study of 19 mildly symptomatic or asymptomatic women, all participants had intellectual abilities within the average range and performed as well as or better than controls in most domains.<xref ref-type="ref" rid="jimd12146-bib-0055">55</xref> However, they showed relative weaknesses in fine motor skills and nonverbal domains. Another study that included primarily asymptomatic individuals without a history of HA episodes revealed no significant difference in IQ between patients with OTCD and a group of individuals without OTCD.<xref ref-type="ref" rid="jimd12146-bib-0056">56</xref> However, subtle deficits in fine motor coordination, executive functioning (especially working memory), and cognitive flexibility were found, albeit only when the cognitive load was relatively high. Self‐reported difficulties in social relationships, as well as anxiety and depression, have also been described in asymptomatic adults with OTCD.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref>
</p>
<p>Although mortality rates may not have greatly improved, some studies reported improvements in cognitive outcomes as treatment paradigms have encompassed ammonia scavenging drugs as well as dietary treatment and early intervention. The pooled rate of intellectual disabilities among females declined from 41% in studies published ≤2000 to 15% &gt;2000. Among males, pooled rates of intellectual disabilities in studies published ≤2000 and &gt; 2000 were 23% and 22%, respectively.</p>
<p>Overall, 24% of the individuals with proximal UCDs had intellectual disability, and the rate of intellectual disability declined (37% ≤2000 vs 20% &gt;2000).</p>
</sec>
</sec>
<sec id="jimd12146-sec-0009">
<label>3.2</label>
<title>Distal (cytosolic) urea cycle disorders</title>
<sec id="jimd12146-sec-0010">
<label>3.2.1</label>
<title>Argininosuccinate synthetase deficiency/citrullinemia type I</title>
<p>Estimated rates of ASSD/citrullinemia type I range from 1:57 000<xref ref-type="ref" rid="jimd12146-bib-0057">57</xref> to 1:250 000 newborns.<xref ref-type="ref" rid="jimd12146-bib-0002">2</xref> ASSD is characterized by elevated citrulline (usually 1000 μmol/L, where normal is &lt;50 μmol/L) and absence of argininosuccinic acid. Ammonia is elevated above 1000 μmol/L in the neonate, where normal is 40‐100 μmol/L. Arginine tends to be in the low to normal range. Glutamine, a surrogate marker for ammonia, tends to be increased as well.<xref ref-type="ref" rid="jimd12146-bib-0058">58</xref> In ASSD, serum glutamine, as compared with serum ammonia, appears to be more closely related to the level of the diffuse pattern of cerebral involvement on magnetic resonance imaging.<xref ref-type="ref" rid="jimd12146-bib-0059">59</xref> Both the severe neonatal or “classic” form and late‐onset form present with HA, although symptoms may be subtle in the later onset form. Symptoms include lethargy, headache, slurred speech, and somnolence. Liver failure also occurs in some patients.<xref ref-type="ref" rid="jimd12146-bib-0060">60</xref> Without treatment, symptoms can progress to seizures, coma, and death. ASSD is now included in the Recommended Uniform Screening Panel that has been adopted in the United States. With early identification, treatment with a protein‐restricted diet and nitrogen scavenger therapy (if needed) can often be initiated before symptom onset. Milder cases detected by NBS may be asymptomatic throughout life or present much later with HA.<xref ref-type="ref" rid="jimd12146-bib-0019">19</xref> Liver transplantation corrects the underlying disorder but does not increase arginine levels or reverse neurologic dysfunction.<xref ref-type="ref" rid="jimd12146-bib-0058">58</xref>
</p>
<p>In the Nassogne series focusing on 33 patients identified from 1972 to 2000, 14 individuals survived.<xref ref-type="ref" rid="jimd12146-bib-0049">49</xref> One of the seven early‐onset cases and two of the seven late‐onset cases had severe neurological symptoms.</p>
<p>An 8‐year‐old boy who presented with HA coma at 8 days of age was treated with protein restriction, arginine, and sodium benzoate. He achieved average cognitive abilities and high‐average scores on gross motor skills, personal‐social, and performance domains of the Griffiths Mental Developmental Stage assessment.<xref ref-type="ref" rid="jimd12146-bib-0061">61</xref> His language score was average, although some vocabulary and fluency difficulties and fine motor weaknesses were noted.</p>
<p>Three patients diagnosed with ASSD through NBS demonstrated a normal neurodevelopmental profile.<xref ref-type="ref" rid="jimd12146-bib-0062">62</xref> Karall et al described the case of a 14‐year‐old boy with late‐onset ASSD who presented with seizure and confusion that resolved upon treatment for elevated ammonia levels.<xref ref-type="ref" rid="jimd12146-bib-0063">63</xref> Later, he had normal neurocognitive development and received no ongoing treatment for ASSD. Another case report described moderate to severe intellectual disabilities in a 31‐year‐old woman who presented with severe HA at neonatal onset and had subsequent episodes of HA and seizures, despite treatment with protein restriction, arginine, and ammonia scavenger drugs.<xref ref-type="ref" rid="jimd12146-bib-0064">64</xref>
</p>
<p>In an analysis of patient data from the UCDC Longitudinal Study, rates of intellectual disabilities were: 18% for the 44 infants and toddlers (ages 6 months to 3 years); 18% among the 23 preschool children age (4‐5 years old); 17% among 42 school‐age children (6‐16 years); and 26% among 19 adults.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> Delays or deficits were noted most commonly in the motor and memory domains. Two preschool children were rated at risk of autism spectrum disorder. Attention deficits were common in the school‐age children. The follow‐up study of enrollees aged ≥3 years identified 35% of 64 patients with intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0065">65</xref>
</p>
<p>Lee et al<xref ref-type="ref" rid="jimd12146-bib-0066">66</xref> compared neuropsychological outcomes in 14 patients with ASSD in terms of age at symptom onset. Among patients with neonatal‐onset ASSD (n = 12), 3 died, four had severe intellectual disabilities, four had moderate intellectual disabilities, and one developed normally. The three patients with late‐onset symptoms had three different outcomes: one died, one had mild intellectual disabilities, and one developed normally. Patients identified presymptomatically (n = 3) fared the best, as all three had normal development and intellectual abilities within the average range.</p>
<p>Across six pooled studies published ≤2000, 34 of 50 patients (68%) with ASSD had intellectual disabilities, whereas the rate declined to 37% (n = 51/137) in eight studies published after 2000.</p>
</sec>
<sec id="jimd12146-sec-0011">
<label>3.2.2</label>
<title>Argininosuccinate lyase deficiency/Argininosuccinic aciduria</title>
<p>ASLD/ASA is the most common distal disorder. ASLD affects approximately 1:49 000<xref ref-type="ref" rid="jimd12146-bib-0067">67</xref> to 1:70 000 newborns.<xref ref-type="ref" rid="jimd12146-bib-0068">68</xref> It is characterized by elevated citrulline and argininosuccinic acid and can lead to HA. Patients without a history of HA may experience seizures and developmental delay.<xref ref-type="ref" rid="jimd12146-bib-0067">67</xref> Other risks include hepatic disease and systemic hypertension.<xref ref-type="ref" rid="jimd12146-bib-0069">69</xref>, <xref ref-type="ref" rid="jimd12146-bib-0070">70</xref> Among UCDs, ASLD is the least likely to result in neonatal death.<xref ref-type="ref" rid="jimd12146-bib-0071">71</xref> Treatment involves a protein‐restricted diet and supplemental arginine. NBS for ASLD initially took place for a limited time in Massachusetts, U.S., from 1969 to 1978<xref ref-type="ref" rid="jimd12146-bib-0067">67</xref> and in Austria from 1978 to 2001.<xref ref-type="ref" rid="jimd12146-bib-0068">68</xref> ASLD later became part of the RUSP (NBS, 2006), leading to the identification of many more cases with mild forms of the condition.<xref ref-type="ref" rid="jimd12146-bib-0072">72</xref> Liver transplantation corrects the deficiency and may prevent neurologic declines, as well.<xref ref-type="ref" rid="jimd12146-bib-0073">73</xref>
</p>
<p>Rates of intellectual disabilities ranged from 83% in a 1998 study<xref ref-type="ref" rid="jimd12146-bib-0048">48</xref> to 6% in a study of individuals identified by NBS.<xref ref-type="ref" rid="jimd12146-bib-0068">68</xref> Among 20 patients in one series, 15 survived long enough to be evaluated, and 9 of these 15 were noted to have moderate to severe intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0074">74</xref> Frequency and severity of HA episodes were not related to outcomes. Tuchman et al<xref ref-type="ref" rid="jimd12146-bib-0075">75</xref> reported that patients with ASLD enrolled in the UCDC study experienced intellectual disability (70%), learning disability (56%), attention‐deficit/hyperactivity disorder (30%), communication disorder (14%), and seizures (32%). In a recent analysis of cross‐sectional data from the UCDC study, particular deficits were noted in fine motor skills, attention, memory, and social interactions.<xref ref-type="ref" rid="jimd12146-bib-0065">65</xref> The percentage of study participants who performed in the range of intellectual disabilities increased with each age cohort: 23% of infants, 24% of preschool children, 38% of school‐age students, and 52% of adults. The mean Full Scale IQ among the 65 individuals aged ≥3 years in the UCDC study was 72 (SD = 21).</p>
<p>Outcomes among individuals identified by NBS may be better, although still somewhat variable. After 13 to 33 years of follow‐up, 8 of 13 individuals identified by NBS had normal intellectual and psychomotor development, while 5 had learning disabilities and borderline IQ (≤85).<xref ref-type="ref" rid="jimd12146-bib-0067">67</xref> Although all patients were initially treated with protein restriction, four of five patients with learning disabilities had discontinued the low‐protein diet early. A similar longitudinal study followed 23 patients diagnosed with ASLD through NBS.<xref ref-type="ref" rid="jimd12146-bib-0068">68</xref> IQ data were available for 17 patients (mean age = 12.4 years); 11 patients had IQs of 90‐136, 5 had IQs of 80‐89, and 1 patient had intellectual disabilities, with an IQ of 61. A case report described a 26‐month‐old male with ASLD who was missed by NBS and presented with nonresponsive focal seizures and experienced intellectual disability, hyperactivity, and severe expressive language delay.<xref ref-type="ref" rid="jimd12146-bib-0076">76</xref>
</p>
<p>A retrospective analysis compared neuropsychological outcomes between individuals with neonatal‐onset (n = 8) and late‐onset (n = 3) ASLD.<xref ref-type="ref" rid="jimd12146-bib-0077">77</xref> Among neonatal‐onset individuals, the DQ/IQ score was near normal at diagnosis but declined slowly thereafter, stabilizing after the age of 4‐6 years. In contrast, individuals with late‐onset ASLD presented with mild to moderate intellectual disabilities at diagnosis with little change over the years. All late‐onset patients had a seizure disorder, whereas three of eight neonatal‐onset individuals had seizures, suggesting a potentially beneficial effect of earlier onset (or earlier recognition of symptoms) and treatment. In contrast, a study of 56 individuals with variable onset of ASLD (early onset, n = 23; late onset, n = 23; newborn screened, n = 10) reported similar long‐term outcomes in all three groups, with a similar neurological phenotype regardless of symptom onset.<xref ref-type="ref" rid="jimd12146-bib-0078">78</xref> In this study, 48 of 52 study participants had mild or moderate intellectual disabilities, primarily affecting speech and learning.</p>
<p>Across seven pooled studies published ≤2000, 23 of 42 (55%) patients had intellectual disabilities and the prevalence of intellectual disabilities increased to 62% (n = 131/212) in 10 studies &gt;2000.</p>
</sec>
<sec id="jimd12146-sec-0012">
<label>3.2.3</label>
<title>Arginase deficiency (ARGD)/Argininemia</title>
<p>ARGD interferes with the breakdown of arginine to urea and ornithine and represents the last step in the urea cycle. The incidence is estimated at 1:950 000 newborns in the United States and Europe.<xref ref-type="ref" rid="jimd12146-bib-0002">2</xref> ARGD is characterized by elevated plasma arginine (2‐5 × normal) and is not usually associated with HA in the neonatal period, although HA may occur at any age.<xref ref-type="ref" rid="jimd12146-bib-0079">79</xref> Spastic diplegia is the most common presenting symptom.<xref ref-type="ref" rid="jimd12146-bib-0080">80</xref> When treated early, ARGD had not been thought to be associated with early developmental delays.<xref ref-type="ref" rid="jimd12146-bib-0081">81</xref> However, more recent reviews indicate that cognitive and motor declines persist and hepatomegaly develops in some children.<xref ref-type="ref" rid="jimd12146-bib-0082">82</xref> Liver transplantation for ARGD corrected arginine abnormalities in one case.<xref ref-type="ref" rid="jimd12146-bib-0083">83</xref>
</p>
<p>The first reported case with neuropsychological testing had an IQ of 70.<xref ref-type="ref" rid="jimd12146-bib-0047">47</xref> A retrospective study examining neuropsychological outcomes in patients with UCDs included seven patients with ARGD. The three patients who survived 5 years had severe intellectual disability (IQ &lt;34).<xref ref-type="ref" rid="jimd12146-bib-0048">48</xref>
</p>
<p>One case report described a 4‐year‐old girl who presented with autistic‐like symptoms and was late diagnosed with ARGD. Her autistic behaviors and hyperactivity resolved after 1 year of treatment with arginine and sodium benzoate plus a protein‐restricted diet, although her IQ was 72.<xref ref-type="ref" rid="jimd12146-bib-0084">84</xref> A boy with progressive gait abnormalities and pyramidal signs was diagnosed with ARGD at 10 years of age.<xref ref-type="ref" rid="jimd12146-bib-0085">85</xref> Despite 7 months of treatment with a protein‐restricted diet and sodium benzoate, his IQ declined from 94 to 82.</p>
<p>Among participants in the UCDC Longitudinal Study, children aged ≤3 years (n = 3) had a mean DQ of 88, and none were noted to have intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> One of the preschool children (age 4‐5 years) scored high on an autism spectrum disorder scale, and 33% of the school‐age children (ages 6‐16 years, n = 6) performed in the range of intellectual disabilities. In a more recent analysis of patient data from the UCDC study, 67% (n = 8/12) of those aged ≥3 years had intellectual disabilities, with a mean IQ of 65 (SD = 12).<xref ref-type="ref" rid="jimd12146-bib-0065">65</xref>
</p>
<p>Martín‐Hernández and colleagues<xref ref-type="ref" rid="jimd12146-bib-0053">53</xref> included two cases of ARGD in their NBS follow‐up study. Neither child performed in the range of intellectual disabilities. In contrast, Rüegger et al reported that seven of eight children identified by NBS experienced intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0019">19</xref>
</p>
<p>Pooled data indicate that 100% (n = 4/4) of children included in reports on ARGD ≤2000 performed in the range of intellectual disabilities, and 63% (n = 15/24) of individuals attained IQ within this range after that time.</p>
<p>Overall, the rate of intellectual disability was 55% among distal UCDs. The rate of intellectual disability derived from studies ≤2000 was 64% vs 53% &gt;2000.</p>
</sec>
</sec>
<sec id="jimd12146-sec-0013">
<label>3.3</label>
<title>Urea cycle mitochondrial transporter defects</title>
<sec id="jimd12146-sec-0014">
<label>3.3.1</label>
<title>Citrin deficiency</title>
<p>Citrin is a mitochondrial aspartate/glutamate carrier providing aspartate for the first cytosolic reaction of the urea cycle. Citrin deficiency generally presents as one of two major clinical pictures: neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) or adult‐onset citrullinemia type II (CTLN2). Failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD) is a third intermediate form of the disease seen in older children.<xref ref-type="ref" rid="jimd12146-bib-0086">86</xref> The neonatal form is unique among the UCDs in that early symptoms abate or completely disappear within the first year of life, and later symptoms do not arise until adulthood. Generally thought to be extremely rare outside of East Asia (mostly Japan),<xref ref-type="ref" rid="jimd12146-bib-0087">87</xref> this UCD has reported incidence rates of 1:100 000 to 1:230 000.<xref ref-type="ref" rid="jimd12146-bib-0086">86</xref> However, a study in Texas in which 10 patients received genetic testing found evidence for Arabic, Pakistani, French Canadian, and Northern European family origin.<xref ref-type="ref" rid="jimd12146-bib-0088">88</xref> NBS with tandem mass spectrometry now takes place in Japan and Taiwan.<xref ref-type="ref" rid="jimd12146-bib-0089">89</xref>, <xref ref-type="ref" rid="jimd12146-bib-0090">90</xref>
</p>
<p>In the neonatal period, the buildup of bile caused by NICCD is associated with failure to thrive and dyslipidemia.<xref ref-type="ref" rid="jimd12146-bib-0086">86</xref> Early signs may involve a “chubby face,” which resolves after 1 year.<xref ref-type="ref" rid="jimd12146-bib-0091">91</xref> Other clinical symptoms may include hypoglycemia, pancreatitis, fatigue, and anorexia.<xref ref-type="ref" rid="jimd12146-bib-0086">86</xref> In NICCD, almost all signs of failure to thrive and liver disease disappear within the first year of life after treatment with medium‐chain triglyceride‐rich formula or lactose‐free formula (for those with secondary galactosemia). In a follow‐up study of 51 children with NICCD,<xref ref-type="ref" rid="jimd12146-bib-0092">92</xref> evidence of liver abnormalities and failure to thrive were noted, but only one child had intellectual disabilities. Hutchin et al<xref ref-type="ref" rid="jimd12146-bib-0087">87</xref> reported on two children with early liver disease but no cognitive or other clinical manifestations after 1 year of age.</p>
<p>The UCDC study included two children with NICCD who received neuropsychological evaluations.<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> During infancy, the children experienced gross motor delay but normal cognition. During preschool, both performed well within the average range, but verbal skills were relatively poorer than nonverbal abilities. In one child evaluated at school age (9 years old), there were no indications of cognitive or behavioral consequences of this condition In a screening of children with neurodevelopmental disabilities, one child with NICCD was identified at age 16 months and subsequently died at 22 months of age because of liver failure and one child had transient developmental delays but improved with age.<xref ref-type="ref" rid="jimd12146-bib-0093">93</xref>
</p>
<p>Citrin deficiency becomes truly problematic in adulthood as CLTN2, which is characterized by high plasma citrulline and ammonia levels with recurrent encephalopathy. Patients with CLTN2 typically present with HA and some experience recurrent neuropsychiatric episodes, including behavior disturbances, nocturnal delirium, disorientation, altered consciousness, convulsive seizures, and coma.<xref ref-type="ref" rid="jimd12146-bib-0086">86</xref> It is critical to distinguish CTLN2 in a patient with HA coma, as its treatment is unique. Unlike treatment for other UCDs, introduction of a high amount of glucose and low amount of protein can be fatal. Asking for the patient's dietary history can be lifesaving, as carbohydrate avoidance and fat‐craving are typical eating habits seen in individuals with CTLN2. Treatment for CTLN2 consists of a diet high in fat and protein, low in carbohydrates, supplemented with arginine, medium‐chain triglycerides, and sodium pyruvate.<xref ref-type="ref" rid="jimd12146-bib-0094">94</xref> Liver transplantation had been the choice of treatment for CTLN2 to eliminate recurrent HA, but oral sodium pyruvate supplementation is now deemed safer and equally effective when started early.<xref ref-type="ref" rid="jimd12146-bib-0095">95</xref>, <xref ref-type="ref" rid="jimd12146-bib-0096">96</xref>
</p>
<p>One case report described an adult who was diagnosed with schizophrenia for many years before finally receiving the correct diagnosis after her HA was recognized. Once treated for her metabolic disorder, her symptoms resolved.<xref ref-type="ref" rid="jimd12146-bib-0097">97</xref>
</p>
<p>Other case reports describe HA and a variety of associated symptoms, including headache, confusion, aggression, delusions, seizures, and coma in the postpartum period or following anesthesia or gastrectomy.<xref ref-type="ref" rid="jimd12146-bib-0098">98</xref>, <xref ref-type="ref" rid="jimd12146-bib-0099">99</xref>, <xref ref-type="ref" rid="jimd12146-bib-0100">100</xref>
</p>
<p>Although cases of NICCD and CTLN2 were described before 2000,<xref ref-type="ref" rid="jimd12146-bib-0101">101</xref>, <xref ref-type="ref" rid="jimd12146-bib-0102">102</xref> no data on cognitive functioning were reported. Pooled data on studies published after 2000 are presented in Table <xref ref-type="table" rid="jimd12146-tbl-0001">1</xref>G. A small number of NICCD cases (n = 3/126, 3%) were noted to have intellectual disabilities.</p>
</sec>
<sec id="jimd12146-sec-0015">
<label>3.3.2</label>
<title>Mitochondrial ornithine transporter 1 deficiency/Hyperornithinemia‐hyperammonemia‐homocitrullinuria syndrome</title>
<p>HHH syndrome is caused by impaired ornithine transport across the inner mitochondrial membrane due to mutations in the ORNT1 transporter.<xref ref-type="ref" rid="jimd12146-bib-0103">103</xref> HHH syndrome is associated with high clinical variability; mild forms manifest with learning difficulties and slight neurological involvement, while symptoms of severe deficiencies include coma, lethargy, hepatic signs, and seizures. Long‐term management consists of a low‐protein diet, citrulline, or arginine supplementation, and, in some patients, nitrogen‐scavenging drugs. Although the incidence of HHH syndrome is unknown, it is estimated at &lt;1:2 000 000.<xref ref-type="ref" rid="jimd12146-bib-0002">2</xref>
</p>
<p>Martinelli et al<xref ref-type="ref" rid="jimd12146-bib-0103">103</xref> published a comprehensive review of previously published cases as well as new cases of HHH syndrome and examined neuropsychological outcomes in 111 patients. The neuropsychological profile of patients was characterized by abnormal behavior (n = 30/51), intellectual disability (n = 58/85), seizures (n = 31/88), lethargy (n = 47/79), and coma (n = 30/94). Among patients with intellectual disability, 36% had mild or moderate intellectual disability (IQ/DQ of 35‐69), while 38% had severe disability (IQ/DQ &lt;35). This series included data from Kim et al<xref ref-type="ref" rid="jimd12146-bib-0104">104</xref> who reported on longitudinal follow‐up of four adults with HHH syndrome. Normal development was reported during infancy and early childhood in all four cases; however, by adulthood, all experienced progression of neurological symptoms and intellectual disability despite attempts at treatment.<xref ref-type="ref" rid="jimd12146-bib-0104">104</xref>
</p>
<p>In the UCDC Longitudinal Study,<xref ref-type="ref" rid="jimd12146-bib-0023">23</xref> three of four infants demonstrated developmental delay but performed within the borderline to average range of intelligence by preschool and school age. The one adult attained an IQ of 100 at age 21 and 84 at age 26 years. Guan et al<xref ref-type="ref" rid="jimd12146-bib-0105">105</xref> reported on three cases of HHH syndrome identified because of clinical symptoms from 2011‐2016. All three experienced developmental delay, and two had moderate intellectual disabilities. Once treated, improvements were noted in behavior and functioning</p>
<p>Pooled data, primarily gleaned from the Martinelli et al<xref ref-type="ref" rid="jimd12146-bib-0103">103</xref> review, suggest modest improvements when treatment is initiated early, but the disease may progress in adulthood. Intellectual disabilities were reported in 72% and 65% of published cases ≤2000 and &gt; 2000, respectively.</p>
</sec>
</sec>
</sec>
<sec id="jimd12146-sec-0016">
<label>4</label>
<title>DISCUSSION</title>
<p>This review presents the neuropsychological manifestations in the eight urea cycle disorders. A “side‐by‐side” examination of published data over the years allows for an assessment of the degree to which changes in management have been successful in preventing intellectual disabilities or improving functioning. The pooled sample included data on cognitive abilities of 1649 individuals reported in 58 citations. A total of 556 patients (34%) functioned in the range of intellectual disabilities. The proportion of cases with intellectual disabilities declined in six disorders, ranging from 7% to 41% (as noted in Table <xref ref-type="table" rid="jimd12146-tbl-0001">1</xref>). Overall, distal UCDs had poorer neurocognitive outcome than proximal UCDs (odds ratio = 3.82; CI = 3.005, 4.876; <italic>P</italic> &lt; 0.001) (See Figure <xref ref-type="fig" rid="jimd12146-fig-0002">2</xref>).</p>
<fig fig-type="Figure" id="jimd12146-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>The rates of intellectual disabilities ≤2000 and &gt;2000 for individual UCDs, proximal and distal UCDs and overall UCDs. <italic>P</italic> values for odds ratios for intellectual deficiencies &gt;2000 compared to ≤2000 were calculated with the Fisher's exact test. *<italic>P</italic> &lt; .05; **<italic>P</italic> &lt; .01; ***<italic>P</italic> &lt; .001; ****<italic>P</italic> &lt; .0001; n.s., not significant. ǂData are only available after the year 2000 for Citrin deficiency. Abbreviations: ARGD, arginase deficiency; ASLD, argininosuccinate lyase deficiency; ASSD, argininosuccinate synthetase deficiency; CPS1D, carbamoyl phosphate synthetase 1 deficiency; HHH, hyperornithinemia‐hyperammonemia‐homocitrullinuria; NAGSD, <italic>N</italic>‐acetylglutamate synthase deficiency; OTCD, ornithine transcarbamylase deficiency</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="JIMD-42-1176-g002"></graphic>
</fig>
<p>The most prominent improvement in neuropsychological outcome after year 2000 was observed in NAGSD. In NAGSD, the prevalence of intellectual disability declined from 50% to 9%, reflecting the efficacy of NCG therapy. The decline observed in females with OTCD (from 41% to 15%) is mainly due to nearly fourfold increase in total number of individuals, with the inclusion of asymptomatic heterozygotes. A similar decrease was not observed for males with OTCD (23% ≤2000 vs 22% after 2000). The improvement observed in cognitive outcomes of neonatal onsets CPS1D, ASSD, and ARGD may be related to effective management of severe HA. Despite similar treatment modalities, the prevalence of intellectual disabilities has increased among individuals with ASLD, which may be related to increased survival rates. The poor cognitive outcome of distal UCDs implicates an insidious impact of cumulative exposure to ammonia, arginine, and citrulline in the long term.<xref ref-type="ref" rid="jimd12146-bib-0065">65</xref>
</p>
<p>Improved treatments have contributed to the survival of many infants, particularly males with OTCD who, nonetheless, experienced early irreversible neurological damage. Across studies, children with neonatal onset of symptoms, early liver failure, and higher levels of ammonia were more likely to have intellectual disabilities.<xref ref-type="ref" rid="jimd12146-bib-0052">52</xref>, <xref ref-type="ref" rid="jimd12146-bib-0053">53</xref>, <xref ref-type="ref" rid="jimd12146-bib-0075">75</xref>, <xref ref-type="ref" rid="jimd12146-bib-0106">106</xref> Early studies reported associations between cognitive outcomes and duration/severity of HA episodes and higher peak ammonia concentration.<xref ref-type="ref" rid="jimd12146-bib-0045">45</xref>, <xref ref-type="ref" rid="jimd12146-bib-0047">47</xref>, <xref ref-type="ref" rid="jimd12146-bib-0048">48</xref>, <xref ref-type="ref" rid="jimd12146-bib-0051">51</xref>, <xref ref-type="ref" rid="jimd12146-bib-0107">107</xref> However, his review suggests that this generalization does not hold true in many cases (eg, Ref. <xref ref-type="ref" rid="jimd12146-bib-0019">19</xref>).</p>
<p>While genotype was sometimes associated with neonatal vs later onset of symptoms, it did not reliably predict occurrence of intellectual disabilities in OTCD,<xref ref-type="ref" rid="jimd12146-bib-0108">108</xref> CPS1,<xref ref-type="ref" rid="jimd12146-bib-0016">16</xref>, <xref ref-type="ref" rid="jimd12146-bib-0028">28</xref> HHH syndrome,<xref ref-type="ref" rid="jimd12146-bib-0109">109</xref> citrullinemia type I,<xref ref-type="ref" rid="jimd12146-bib-0066">66</xref> and probably in all the other UCDs, as well. Earlier treatment initiation (diet in less severe cases and ammonia scavengers or liver transplantation in severe cases) led to better outcomes in most studies,<xref ref-type="ref" rid="jimd12146-bib-0007">7</xref>, <xref ref-type="ref" rid="jimd12146-bib-0008">8</xref>, <xref ref-type="ref" rid="jimd12146-bib-0045">45</xref>, <xref ref-type="ref" rid="jimd12146-bib-0047">47</xref>, <xref ref-type="ref" rid="jimd12146-bib-0061">61</xref>, <xref ref-type="ref" rid="jimd12146-bib-0084">84</xref>, <xref ref-type="ref" rid="jimd12146-bib-0110">110</xref> whereas lack of treatment or noncompliance with treatment resulted in poorer cognitive outcomes.<xref ref-type="ref" rid="jimd12146-bib-0056">56</xref>, <xref ref-type="ref" rid="jimd12146-bib-0067">67</xref>, <xref ref-type="ref" rid="jimd12146-bib-0068">68</xref>
</p>
<p>Recent studies provide evidence for other variables that explain diversity of outcomes, including number of HA episodes, cumulative exposure to moderately abnormal biochemical levels,<xref ref-type="ref" rid="jimd12146-bib-0065">65</xref> and other epigenetic factors or environmental stressors, such as alcohol consumption,<xref ref-type="ref" rid="jimd12146-bib-0111">111</xref> menses,<xref ref-type="ref" rid="jimd12146-bib-0025">25</xref> or pregnancy in women.<xref ref-type="ref" rid="jimd12146-bib-0026">26</xref>
</p>
<p>The varied outcomes present challenges in answering the question of whether certain brain regions are more likely to be affected or whether the specific deficits noted reflect global intellectual and developmental impairment. A recent publication by Buerger et al<xref ref-type="ref" rid="jimd12146-bib-0112">112</xref> argues for a global impact in OTCD.</p>
<p>Neuropsychological deficits in patients with UCD may be reversible with effective therapy, as was demonstrated in two 12‐month safety extension trials showing that glycerol phenylbutyrate improved executive function skills (including behavioral regulation, goal setting, planning, and self‐monitoring) when used as maintenance therapy in children.<xref ref-type="ref" rid="jimd12146-bib-0110">110</xref> Liver transplantation was also associated with superior neurodevelopmental outcomes among patients with ammonia concentrations ≥300 μmol/L.<xref ref-type="ref" rid="jimd12146-bib-0008">8</xref>
</p>
<p>The major limitations of this review are that most studies included heterogeneous samples and lacked control individuals for comparison. Studies including individuals identified by NBS were likely to detect far more cases of mild UCDs and may have led to misclassification of cases as late onset when treatment prevented early‐onset of symptoms. Almost none of the studies accounted for infants who died when diagnoses occurred before developmental assessment or post mortem. The pooled analyses provide only a rough picture of intellectual outcomes in UCDs, especially since not all cases were accounted for; the year 2000 as a dividing point for assumed treatment availability is arbitrary, and it is possible that the most affected or least affected individuals did not receive neuropsychological evaluations. Furthermore, patient samples may have included some overlap and some studies and case reports may have been missed.</p>
<p>Nonetheless, this review identified important design elements for natural history studies and eventual clinical trials. As shown by Rüegger et al,<xref ref-type="ref" rid="jimd12146-bib-0019">19</xref> timing of diagnosis should be considered. In the group of patients whose diagnosis was delayed &gt;1 year after symptom onset, 75% were affected by cognitive impairment compared with 46% if the delay was ≤1 year. Psychiatric and behavioral outcomes need to be assessed, as evidenced by reports noting psychosis, depression, anxiety, and/or social difficulties in every UCD. These symptoms may be due to neurological perturbations or to the experience of having a chronic illness. Attention‐deficit/hyperactivity disorder and behaviors associated with autism spectrum disorder were frequently reported, suggesting that these symptoms should also be assessed. Laboratory studies need to be included at regular intervals, even when the individual is not showing symptoms, so that correlations between severity of outcome and metabolic status can be reliably identified.<xref ref-type="ref" rid="jimd12146-bib-0065">65</xref> Adequate functioning at school or within the community does not mean that the individual is unaffected by the UCD, as was apparent in studies of adults with OTCD,<xref ref-type="ref" rid="jimd12146-bib-0055">55</xref>, <xref ref-type="ref" rid="jimd12146-bib-0056">56</xref> thus reinforcing the need for regular neuropsychological evaluation.</p>
<p>Finally, this review supports efforts to develop novel therapies by highlighting the continued risks to neuropsychological functioning in individuals with UCDs. Except for citrin deficiencies, rates of intellectual disabilities remain high. Clearly, it is time to “raise the bar” in expectations for treatment. Earlier and more accurate diagnoses are now possible through genetic testing. NBS is becoming routine for many UCDs and is on the horizon for others. Perhaps most importantly, treatments that were once only imagined, such as enzyme replacement, genetic therapies, and drugs to enhance alternative metabolic pathways, are now possible.</p>
</sec>
<sec id="jimd12146-sec-0018" sec-type="COI-statement">
<title>CONFLICT OF INTERESTS</title>
<p>S.E. Waisbren is a consultant to Horizon, Ultragenyx and Shire on the psychological attributes of urea cycle disorders. She received no financial support for work on this manuscript. She is also a member of the Urea Cycle Disorders Consortium (UCDC; U54HD061221), which is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the Office of Rare Diseases Research (ORDR), the National Center for Advancing Translational Science (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). A.K. Stefanatos has nothing to disclose. T.M.Y. Kok is an employee of and has stock in Horizon. B. Ozturk‐Hismi received grant support from The Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (TUBITAK‐1059B191601447).</p>
</sec>
<sec id="jimd12146-sec-0019">
<title>AUTHOR CONTRIBUTIONS</title>
<p>S.E. Waisbren, PhD, contributed to the design and literature review and was the primary author of the manuscript. A.K. Stefanatos, PhD, contributed to the literature review and helped edit the final manuscript. T.M.Y. Kok, BSc Pharm, contributed to the literature review and edited the manuscript. B. Ozturk‐Hismi, MD, contributed to the literature review, co‐authored sections of the manuscript, and edited the final manuscript.</p>
</sec>
<sec id="jimd12146-sec-0003">
<title>ETHICS APPROVAL/CONSENT</title>
<p>This article is a review of published literature and does not contain any new studies with human or animal subjects performed by the authors.</p>
</sec>
<sec id="jimd12146-sec-0020">
<title>GUARANTOR</title>
<p>S.E. Waisbren, PhD, is the guarantor for the article, accepts full responsibility for the work, and controlled the decision to publish.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="jimd12146-supitem-0001">
<caption>
<p>Data S1 Supporting Information</p>
</caption>
<media xlink:href="JIMD-42-1176-s001.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="jimd12146-sec-0017">
<title>ACKNOWLEDGMENTS</title>
<p>Megan Francis‐Sedlak, PhD of Horizon Therapeutics, Plc, Amanda Sheldon, PhD, CMPP, of inScience Communications, Springer Healthcare Philadelphia, PA, USA, and Hong‐Ye Gao, PhD provided medical writing and statistical support funded by Horizon. Horizon supported the development of this manuscript. The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsor.</p>
</ack>
<ref-list content-type="cited-references" id="jimd12146-bibl-0001">
<title>REFERENCES</title>
<ref id="jimd12146-bib-0001">
<label>1</label>
<mixed-citation id="jimd12146-cit-0001" publication-type="book">
<string-name>
<surname>Ah Mew</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Gropman</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Lanpher</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Summar</surname>
<given-names>ML</given-names>
</string-name>. <chapter-title>Urea cycle disorders overview. 2003 Apr 29 [updated 2017 Jun 22]</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Ardinger</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name></person-group>, et al., eds. <source xml:lang="en"/>GeneReviews® [Internet]. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; <year>2017</year> 1993‐2019.Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1217/">https://www.ncbi.nlm.nih.gov/books/NBK1217/</ext-link>.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0002">
<label>2</label>
<mixed-citation id="jimd12146-cit-0002" publication-type="journal">
<string-name>
<surname>Summar</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Koelker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Freedenberg</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>The incidence of urea cycle disorders</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2013</year>;<volume>110</volume>:<fpage>179</fpage>‐<lpage>180</lpage>.<pub-id pub-id-type="pmid">23972786</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0003">
<label>3</label>
<mixed-citation id="jimd12146-cit-0003" publication-type="journal">
<string-name>
<surname>Summar</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Mew</surname>
<given-names>NA</given-names>
</string-name>. <article-title>Inborn errors of metabolism with Hyperammonemia: urea cycle defects and related disorders</article-title>. <source xml:lang="en"/>Pediatr Clin North Am. <year>2018</year>;<volume>65</volume>:<fpage>231</fpage>‐<lpage>246</lpage>.<pub-id pub-id-type="pmid">29502911</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0004">
<label>4</label>
<mixed-citation id="jimd12146-cit-0004" publication-type="journal">
<string-name>
<surname>Husson</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Schiff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fouilhoux</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study</article-title>. <source xml:lang="en"/>Orphanet J Rare Dis. <year>2016</year>;<volume>11</volume>:<fpage>127</fpage>.<pub-id pub-id-type="pmid">27663197</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0005">
<label>5</label>
<mixed-citation id="jimd12146-cit-0005" publication-type="journal">
<string-name>
<surname>Haberle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Boddaert</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Burlina</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Suggested guidelines for the diagnosis and management of urea cycle disorders</article-title>. <source xml:lang="en"/>Orphanet J Rare Dis. <year>2012</year>;<volume>7</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">22642880</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0006">
<label>6</label>
<mixed-citation id="jimd12146-cit-0006" publication-type="journal">
<string-name>
<surname>El‐Hattab</surname>
<given-names>AW</given-names>
</string-name>. <article-title>Inborn errors of metabolism</article-title>. <source xml:lang="en"/>Clin Perinatol. <year>2015</year>;<volume>42</volume>:<fpage>413</fpage>‐<lpage>439</lpage>.<pub-id pub-id-type="pmid">26042912</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0007">
<label>7</label>
<mixed-citation id="jimd12146-cit-0007" publication-type="journal">
<string-name>
<surname>Foschi</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Morelli</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Savini</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Urea cycle disorders: a case report of a successful treatment with liver transplant and a literature review</article-title>. <source xml:lang="en"/>World J Gastroenterol. <year>2015</year>;<volume>21</volume>:<fpage>4063</fpage>‐<lpage>4068</lpage>.<pub-id pub-id-type="pmid">25852294</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0008">
<label>8</label>
<mixed-citation id="jimd12146-cit-0008" publication-type="journal">
<string-name>
<surname>Kido</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Momosaki</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Liver transplantation may prevent neurodevelopmental deterioration in high‐risk patients with urea cycle disorders</article-title>. <source xml:lang="en"/>Pediatr Transplant. <year>2017</year>;<volume>21</volume>(<issue>6</issue>):e12987.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0009">
<label>9</label>
<mixed-citation id="jimd12146-cit-0009" publication-type="journal">
<string-name>
<surname>Unsinn</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Valayannopoulos</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Clinical course of 63 patients with neonatal onset urea cycle disorders in the years 2001‐2013</article-title>. <source xml:lang="en"/>Orphanet J Rare Dis. <year>2016</year>;<volume>11</volume>:<fpage>116</fpage>.<pub-id pub-id-type="pmid">27538463</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0010">
<label>10</label>
<mixed-citation id="jimd12146-cit-0010" publication-type="journal">
<string-name>
<surname>Batshaw</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Brusilow</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Waber</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion</article-title>. <source xml:lang="en"/>N Engl J Med. <year>1982</year>;<volume>306</volume>:<fpage>1387</fpage>‐<lpage>1392</lpage>.<pub-id pub-id-type="pmid">7078580</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0011">
<label>11</label>
<mixed-citation id="jimd12146-cit-0011" publication-type="miscellaneous">
<string-name>
<surname>Summar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Malley</surname>
<given-names>M</given-names>
</string-name> (<year>2017</year>) <italic>Carbamoyl Phosphate Synthetase I Deficiency</italic> Available from <ext-link ext-link-type="uri" xlink:href="https://rarediseases.org/rare-diseases/carbamoyl-phosphate-synthetase-i-deficiency/">https://rarediseases.org/rare-diseases/carbamoyl-phosphate-synthetase-i-deficiency/</ext-link>
</mixed-citation>
</ref>
<ref id="jimd12146-bib-0012">
<label>12</label>
<mixed-citation id="jimd12146-cit-0012" publication-type="journal">
<string-name>
<surname>Takeoka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Soman</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Shih</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Caviness</surname>
<given-names>VS</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Krishnamoorthy</surname>
<given-names>KS</given-names>
</string-name>. <article-title>Carbamyl phosphate synthetase 1 deficiency: a destructive encephalopathy</article-title>. <source xml:lang="en"/>Pediatr Neurol. <year>2001</year>;<volume>24</volume>:<fpage>193</fpage>‐<lpage>199</lpage>.<pub-id pub-id-type="pmid">11301219</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0013">
<label>13</label>
<mixed-citation id="jimd12146-cit-0013" publication-type="journal">
<string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lei</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mu</surname>
<given-names>D</given-names>
</string-name>. <article-title>Neonatal‐onset carbamoyl phosphate synthetase I deficiency: a case report</article-title>. <source xml:lang="en"/>Medicine (Baltimore). <year>2017</year>;<volume>96</volume>:<elocation-id>e7365</elocation-id>.<pub-id pub-id-type="pmid">28658158</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0014">
<label>14</label>
<mixed-citation id="jimd12146-cit-0014" publication-type="journal">
<string-name>
<surname>Enns</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>GT</given-names>
</string-name>, <string-name>
<surname>Rhead</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Brusilow</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Hamosh</surname>
<given-names>A</given-names>
</string-name>. <article-title>Survival after treatment with phenylacetate and benzoate for urea‐cycle disorders</article-title>. <source xml:lang="en"/>N Engl J Med. <year>2007</year>;<volume>356</volume>:<fpage>2282</fpage>‐<lpage>2292</lpage>.<pub-id pub-id-type="pmid">17538087</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0015">
<label>15</label>
<mixed-citation id="jimd12146-cit-0015" publication-type="journal">
<string-name>
<surname>Diez‐Fernandez</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Haberle</surname>
<given-names>J</given-names>
</string-name>. <article-title>Targeting CPS1 in the treatment of carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder</article-title>. <source xml:lang="en"/>Expert Opin Ther Targets. <year>2017</year>;<volume>21</volume>:<fpage>391</fpage>‐<lpage>399</lpage>.<pub-id pub-id-type="pmid">28281899</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0016">
<label>16</label>
<mixed-citation id="jimd12146-cit-0016" publication-type="journal">
<string-name>
<surname>Klaus</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vermeulen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Minassian</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Highly variable clinical phenotype of carbamylphosphate synthetase 1 deficiency in one family: an effect of allelic variation in gene expression?</article-title>
<source xml:lang="en"/>Clin Genet. <year>2009</year>;<volume>76</volume>:<fpage>263</fpage>‐<lpage>269</lpage>.<pub-id pub-id-type="pmid">19793055</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0017">
<label>17</label>
<mixed-citation id="jimd12146-cit-0017" publication-type="journal">
<string-name>
<surname>Kosho</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kaneko</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tamura</surname>
<given-names>M</given-names>
</string-name>. <article-title>A case of neonatal‐onset carbamoyl‐phosphate synthase I deficiency treated by continuous haemodiafiltration</article-title>. <source xml:lang="en"/>Eur J Pediatr. <year>2000</year>;<volume>159</volume>:<fpage>629</fpage>‐<lpage>630</lpage>.<pub-id pub-id-type="pmid">10968246</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0018">
<label>18</label>
<mixed-citation id="jimd12146-cit-0018" publication-type="journal">
<string-name>
<surname>Ali</surname>
<given-names>EZ</given-names>
</string-name>, <string-name>
<surname>Khalid</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Yunus</surname>
<given-names>ZM</given-names>
</string-name>, et al. <article-title>Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients</article-title>. <source xml:lang="en"/>Eur J Pediatr. <year>2016</year>;<volume>175</volume>:<fpage>339</fpage>‐<lpage>346</lpage>.<pub-id pub-id-type="pmid">26440671</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0019">
<label>19</label>
<mixed-citation id="jimd12146-cit-0019" publication-type="journal">
<string-name>
<surname>Rüegger</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Lindner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ballhausen</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Cross‐sectional observational study of 208 patients with non‐classical urea cycle disorders</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2014</year>;<volume>37</volume>:<fpage>21</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">23780642</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0020">
<label>20</label>
<mixed-citation id="jimd12146-cit-0020" publication-type="journal">
<string-name>
<surname>Ono</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Suto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sakano</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Furue</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohta</surname>
<given-names>T</given-names>
</string-name>. <article-title>A case of carbamoyl phosphate synthetase 1 deficiency presenting symptoms at one month of age</article-title>. <source xml:lang="en"/>Brain Dev. <year>2009</year>;<volume>31</volume>:<fpage>779</fpage>‐<lpage>781</lpage>.<pub-id pub-id-type="pmid">19167850</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0021">
<label>21</label>
<mixed-citation id="jimd12146-cit-0021" publication-type="journal">
<string-name>
<surname>Kurokawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yorifuji</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kawai</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Molecular and clinical analyses of Japanese patients with carbamoylphosphate synthetase 1 (CPS1) deficiency</article-title>. <source xml:lang="en"/>J Hum Genet. <year>2007</year>;<volume>52</volume>:<fpage>349</fpage>‐<lpage>354</lpage>.<pub-id pub-id-type="pmid">17310273</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0022">
<label>22</label>
<mixed-citation id="jimd12146-cit-0022" publication-type="journal">
<string-name>
<surname>Funghini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thusberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Spada</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Carbamoyl phosphate synthetase 1 deficiency in Italy: clinical and genetic findings in a heterogeneous cohort</article-title>. <source xml:lang="en"/>Gene. <year>2012</year>;<volume>493</volume>:<fpage>228</fpage>‐<lpage>234</lpage>.<pub-id pub-id-type="pmid">22173106</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0023">
<label>23</label>
<mixed-citation id="jimd12146-cit-0023" publication-type="journal">
<string-name>
<surname>Waisbren</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Gropman</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Batshaw</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Improving long term outcomes in urea cycle disorders‐report from the urea cycle disorders consortium</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2016</year>;<volume>39</volume>:<fpage>573</fpage>‐<lpage>584</lpage>.<pub-id pub-id-type="pmid">27215558</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0024">
<label>24</label>
<mixed-citation id="jimd12146-cit-0024" publication-type="journal">
<string-name>
<surname>Serrano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martins</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Perez‐Duenas</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Neuropsychiatric manifestations in late‐onset urea cycle disorder patients</article-title>. <source xml:lang="en"/>J Child Neurol. <year>2010</year>;<volume>25</volume>:<fpage>352</fpage>‐<lpage>358</lpage>.<pub-id pub-id-type="pmid">19684305</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0025">
<label>25</label>
<mixed-citation id="jimd12146-cit-0025" publication-type="journal">
<string-name>
<surname>Wakutani</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakayasu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeshima</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>A case of late‐onset carbamoyl phosphate synthetase I deficiency, presenting periodic psychotic episodes coinciding with menstrual periods</article-title>. <source xml:lang="en"/>Rinsho Shinkeigaku. <year>2001</year>;<volume>41</volume>:<fpage>780</fpage>‐<lpage>785</lpage>.<pub-id pub-id-type="pmid">12080609</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0026">
<label>26</label>
<mixed-citation id="jimd12146-cit-0026" publication-type="journal">
<string-name>
<surname>Eather</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Coman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lander</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>McGill</surname>
<given-names>J</given-names>
</string-name>. <article-title>Carbamyl phosphate synthase deficiency: diagnosed during pregnancy in a 41‐year‐old</article-title>. <source xml:lang="en"/>J Clin Neurosci. <year>2006</year>;<volume>13</volume>:<fpage>702</fpage>‐<lpage>706</lpage>.<pub-id pub-id-type="pmid">16860720</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0027">
<label>27</label>
<mixed-citation id="jimd12146-cit-0027" publication-type="journal">
<string-name>
<surname>Bates</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Burnett</surname>
<given-names>JR</given-names>
</string-name>, et al. <article-title>Late‐onset carbamoyl phosphate synthetase 1 deficiency in an adult cured by liver transplantation</article-title>. <source xml:lang="en"/>Liver Transpl. <year>2011</year>;<volume>17</volume>:<fpage>1481</fpage>‐<lpage>1484</lpage>.<pub-id pub-id-type="pmid">21837743</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0028">
<label>28</label>
<mixed-citation id="jimd12146-cit-0028" publication-type="journal">
<string-name>
<surname>Ah Mew</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Caldovic</surname>
<given-names>L</given-names>
</string-name>. <article-title>N‐acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment</article-title>. <source xml:lang="en"/>Appl Clin Genet. <year>2011</year>;<volume>4</volume>:<fpage>127</fpage>‐<lpage>135</lpage>.<pub-id pub-id-type="pmid">23776373</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0029">
<label>29</label>
<mixed-citation id="jimd12146-cit-0029" publication-type="journal">
<string-name>
<surname>Takayanagi</surname>
<given-names>M</given-names>
</string-name>. <article-title>A commentary on short‐term efficacy of N‐carbamylglutamate in a patient with N‐acetylglutamate synthase deficiency</article-title>. <source xml:lang="en"/>J Hum Genet. <year>2015</year>;<volume>60</volume>:<fpage>347</fpage>.<pub-id pub-id-type="pmid">25994872</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0030">
<label>30</label>
<mixed-citation id="jimd12146-cit-0030" publication-type="journal">
<string-name>
<surname>Bachmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Brandis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weissenbarth‐Riedel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Burghard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Colombo</surname>
<given-names>JP</given-names>
</string-name>. <article-title>N‐acetylglutamate synthetase deficiency, a second patient</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1988</year>;<volume>11</volume>:<fpage>191</fpage>‐<lpage>193</lpage>.<pub-id pub-id-type="pmid">3139931</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0031">
<label>31</label>
<mixed-citation id="jimd12146-cit-0031" publication-type="journal">
<string-name>
<surname>Schubiger</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bachmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Barben</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Colombo</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Tonz</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Schupbach</surname>
<given-names>D</given-names>
</string-name>. <article-title>N‐acetylglutamate synthetase deficiency: diagnosis, management and follow‐up of a rare disorder of ammonia detoxication</article-title>. <source xml:lang="en"/>Eur J Pediatr. <year>1991</year>;<volume>150</volume>:<fpage>353</fpage>‐<lpage>356</lpage>.<pub-id pub-id-type="pmid">2044610</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0032">
<label>32</label>
<mixed-citation id="jimd12146-cit-0032" publication-type="journal">
<string-name>
<surname>Pandya</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hommes</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>JC</given-names>
</string-name>. <article-title>N‐acetylglutamate synthetase deficiency: clinical and laboratory observations</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1991</year>;<volume>14</volume>:<fpage>685</fpage>‐<lpage>690</lpage>.<pub-id pub-id-type="pmid">1779615</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0033">
<label>33</label>
<mixed-citation id="jimd12146-cit-0033" publication-type="journal">
<string-name>
<surname>Burlina</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Bachmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wermuth</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Partial N‐acetylglutamate synthetase deficiency: a new case with uncontrollable movement disorders</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1992</year>;<volume>15</volume>:<fpage>395</fpage>‐<lpage>398</lpage>.<pub-id pub-id-type="pmid">1405478</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0034">
<label>34</label>
<mixed-citation id="jimd12146-cit-0034" publication-type="journal">
<string-name>
<surname>Forget</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>van Oosterhout</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bakker</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Wermuth</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Vles</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Spaapen</surname>
<given-names>LJ</given-names>
</string-name>. <article-title>Partial N‐acetyl‐glutamate synthetase deficiency masquerading as a valproic acid‐induced Reye‐like syndrome</article-title>. <source xml:lang="en"/>Acta Paediatr. <year>1999</year>;<volume>88</volume>:<fpage>1409</fpage>‐<lpage>1411</lpage>.<pub-id pub-id-type="pmid">10626533</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0035">
<label>35</label>
<mixed-citation id="jimd12146-cit-0035" publication-type="journal">
<string-name>
<surname>Guffon</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Vianey‐Saban</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bourgeois</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rabier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Colombo</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Guibaud</surname>
<given-names>P</given-names>
</string-name>. <article-title>A new neonatal case of N‐acetylglutamate synthase deficiency treated by carbamylglutamate</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1995</year>;<volume>18</volume>:<fpage>61</fpage>‐<lpage>65</lpage>.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0036">
<label>36</label>
<mixed-citation id="jimd12146-cit-0036" publication-type="journal">
<string-name>
<surname>Hinnie</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Colombo</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Wermuth</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dryburgh</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>N‐Acetylglutamate synthetase deficiency responding to carbamylglutamate</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1997</year>;<volume>20</volume>:<fpage>839</fpage>‐<lpage>840</lpage>.<pub-id pub-id-type="pmid">9427158</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0037">
<label>37</label>
<mixed-citation id="jimd12146-cit-0037" publication-type="journal">
<string-name>
<surname>Morris</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Richmond</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Oddie</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Pourfarzam</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Worthington</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>JV</given-names>
</string-name>. <article-title>N‐acetylglutamate synthetase deficiency: favourable experience with carbamylglutamate</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1998</year>;<volume>21</volume>:<fpage>867</fpage>‐<lpage>868</lpage>.<pub-id pub-id-type="pmid">9870213</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0038">
<label>38</label>
<mixed-citation id="jimd12146-cit-0038" publication-type="journal">
<string-name>
<surname>Plecko</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Erwa</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wermuth</surname>
<given-names>B</given-names>
</string-name>. <article-title>Partial N‐acetylglutamate synthetase deficiency in a 13‐year‐old girl: diagnosis and response to treatment with N‐carbamylglutamate</article-title>. <source xml:lang="en"/>Eur J Pediatr. <year>1998</year>;<volume>157</volume>:<fpage>996</fpage>‐<lpage>998</lpage>.<pub-id pub-id-type="pmid">9877039</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0039">
<label>39</label>
<mixed-citation id="jimd12146-cit-0039" publication-type="journal">
<string-name>
<surname>Vockley</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vockley</surname>
<given-names>CMW</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>S‐P</given-names>
</string-name>, et al. <article-title>Normal N‐acetylglutamate concentration measured in liver from a new patient with N‐acetylglutamate synthetase deficiency: physiologic and biochemical implications</article-title>. <source xml:lang="en"/>Biochem Med Metab Biol. <year>1992</year>;<volume>47</volume>:<fpage>38</fpage>‐<lpage>46</lpage>.<pub-id pub-id-type="pmid">1562355</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0040">
<label>40</label>
<mixed-citation id="jimd12146-cit-0040" publication-type="journal">
<string-name>
<surname>Gessler</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Buchal</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Schwenk</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Wermuth</surname>
<given-names>B</given-names>
</string-name>. <article-title>Favourable long‐term outcome after immediate treatment of neonatal hyperammonemia due to N‐acetylglutamate synthase deficiency</article-title>. <source xml:lang="en"/>Eur J Pediatr. <year>2010</year>;<volume>169</volume>:<fpage>197</fpage>‐<lpage>199</lpage>.<pub-id pub-id-type="pmid">19533169</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0041">
<label>41</label>
<mixed-citation id="jimd12146-cit-0041" publication-type="journal">
<string-name>
<surname>Nordenstrom</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Halldin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hallberg</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Alm</surname>
<given-names>J</given-names>
</string-name>. <article-title>A trial with N‐carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2007</year>;<volume>30</volume>:<fpage>400</fpage>.<pub-id pub-id-type="pmid">17510757</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0042">
<label>42</label>
<mixed-citation id="jimd12146-cit-0042" publication-type="journal">
<string-name>
<surname>Reigstad</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Woldseth</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Haberle</surname>
<given-names>J</given-names>
</string-name>. <article-title>Normal neurological development during infancy despite massive Hyperammonemia in early treated NAGS deficiency</article-title>. <source xml:lang="en"/>JIMD Rep. <year>2017</year>;<volume>37</volume>:<fpage>45</fpage>‐<lpage>47</lpage>.<pub-id pub-id-type="pmid">28275973</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0043">
<label>43</label>
<mixed-citation id="jimd12146-cit-0043" publication-type="journal">
<string-name>
<surname>Sancho‐Vaello</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Marco‐Marin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gougeard</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Understanding N‐acetyl‐L‐glutamate synthase deficiency: mutational Spectrum, impact of clinical mutations on enzyme functionality, and structural considerations</article-title>. <source xml:lang="en"/>Hum Mutat. <year>2016</year>;<volume>37</volume>:<fpage>679</fpage>‐<lpage>694</lpage>.<pub-id pub-id-type="pmid">27037498</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0044">
<label>44</label>
<mixed-citation id="jimd12146-cit-0044" publication-type="book">
<string-name>
<surname>Lichter‐Konecki</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Caldovic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Morizono</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>K</given-names>
</string-name> (<year>1993</year>) <chapter-title>Ornithine Transcarbamylase deficiency. 2013 Aug 29 [updated 2016 Apr 14]</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Ardinger</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name></person-group>, et al., editors. <source xml:lang="en"/>GeneReviews® [Internet]. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; 1993‐2019. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK154378/">https://www.ncbi.nlm.nih.gov/books/NBK154378/</ext-link>
</mixed-citation>
</ref>
<ref id="jimd12146-bib-0045">
<label>45</label>
<mixed-citation id="jimd12146-cit-0045" publication-type="journal">
<string-name>
<surname>Msall</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Batshaw</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Suss</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Brusilow</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Mellits</surname>
<given-names>ED</given-names>
</string-name>. <article-title>Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea‐cycle enzymopathies</article-title>. <source xml:lang="en"/>N Engl J Med. <year>1984</year>;<volume>310</volume>:<fpage>1500</fpage>‐<lpage>1505</lpage>.<pub-id pub-id-type="pmid">6717540</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0046">
<label>46</label>
<mixed-citation id="jimd12146-cit-0046" publication-type="journal">
<string-name>
<surname>Rowe</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Brusilow</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Natural history of symptomatic partial ornithine transcarbamylase deficiency</article-title>. <source xml:lang="en"/>N Engl J Med. <year>1986</year>;<volume>314</volume>:<fpage>541</fpage>‐<lpage>547</lpage>.<pub-id pub-id-type="pmid">3945292</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0047">
<label>47</label>
<mixed-citation id="jimd12146-cit-0047" publication-type="journal">
<string-name>
<surname>Msall</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Monahan</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Chapanis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Batshaw</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Cognitive development in children with inborn errors of urea synthesis</article-title>. <source xml:lang="en"/>Acta Paediatr Jpn. <year>1988</year>;<volume>30</volume>:<fpage>435</fpage>‐<lpage>441</lpage>.<pub-id pub-id-type="pmid">3150233</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0048">
<label>48</label>
<mixed-citation id="jimd12146-cit-0048" publication-type="journal">
<string-name>
<surname>Uchino</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Endo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>I</given-names>
</string-name>. <article-title>Neurodevelopmental outcome of long‐term therapy of urea cycle disorders in Japan</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1998</year>;<volume>21</volume>(<issue>Suppl 1</issue>):<fpage>151</fpage>‐<lpage>159</lpage>.<pub-id pub-id-type="pmid">9686352</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0049">
<label>49</label>
<mixed-citation id="jimd12146-cit-0049" publication-type="journal">
<string-name>
<surname>Nassogne</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Heron</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Touati</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rabier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Saudubray</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Urea cycle defects: management and outcome</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2005</year>;<volume>28</volume>:<fpage>407</fpage>‐<lpage>414</lpage>.<pub-id pub-id-type="pmid">15868473</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0050">
<label>50</label>
<mixed-citation id="jimd12146-cit-0050" publication-type="journal">
<string-name>
<surname>Nicolaides</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Liebsch</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dale</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Surtees</surname>
<given-names>R</given-names>
</string-name>. <article-title>Neurological outcome of patients with ornithine carbamoyltransferase deficiency</article-title>. <source xml:lang="en"/>Arch Dis Child. <year>2002</year>;<volume>86</volume>:<fpage>54</fpage>‐<lpage>56</lpage>.<pub-id pub-id-type="pmid">11806886</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0051">
<label>51</label>
<mixed-citation id="jimd12146-cit-0051" publication-type="journal">
<string-name>
<surname>Bachmann</surname>
<given-names>C</given-names>
</string-name>. <article-title>Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation</article-title>. <source xml:lang="en"/>Eur J Pediatr. <year>2003</year>;<volume>162</volume>:<fpage>410</fpage>‐<lpage>416</lpage>.<pub-id pub-id-type="pmid">12684900</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0052">
<label>52</label>
<mixed-citation id="jimd12146-cit-0052" publication-type="journal">
<string-name>
<surname>Krivitzky</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Babikian</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Burk‐Paull</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Batshaw</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders</article-title>. <source xml:lang="en"/>Pediatr Res. <year>2009</year>;<volume>66</volume>:<fpage>96</fpage>‐<lpage>101</lpage>.<pub-id pub-id-type="pmid">19287347</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0053">
<label>53</label>
<mixed-citation id="jimd12146-cit-0053" publication-type="journal">
<string-name>
<surname>Martín‐Hernández</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Aldamiz‐Echevarria</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Castejon‐Ponce</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Urea cycle disorders in Spain: an observational, cross‐sectional and multicentric study of 104 cases</article-title>. <source xml:lang="en"/>Orphanet J Rare Dis. <year>2014</year>;<volume>9</volume>:<fpage>187</fpage>.<pub-id pub-id-type="pmid">25433810</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0054">
<label>54</label>
<mixed-citation id="jimd12146-cit-0054" publication-type="journal">
<string-name>
<surname>Sprouse</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Helman</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Investigating neurological deficits in carriers and affected patients with ornithine transcarbamylase deficiency</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2014</year>;<volume>113</volume>:<fpage>136</fpage>‐<lpage>141</lpage>.<pub-id pub-id-type="pmid">24881970</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0055">
<label>55</label>
<mixed-citation id="jimd12146-cit-0055" publication-type="journal">
<string-name>
<surname>Gyato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wray</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>ZJ</given-names>
</string-name>, <string-name>
<surname>Yudkoff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Batshaw</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency</article-title>. <source xml:lang="en"/>Ann Neurol. <year>2004</year>;<volume>55</volume>:<fpage>80</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">14705115</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0056">
<label>56</label>
<mixed-citation id="jimd12146-cit-0056" publication-type="journal">
<string-name>
<surname>Gropman</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Prust</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Breeden</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fricke</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>VanMeter</surname>
<given-names>J</given-names>
</string-name>. <article-title>Urea cycle defects and hyperammonemia: effects on functional imaging</article-title>. <source xml:lang="en"/>Metab Brain Dis. <year>2013</year>;<volume>28</volume>:<fpage>269</fpage>‐<lpage>275</lpage>.<pub-id pub-id-type="pmid">23149878</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0057">
<label>57</label>
<mixed-citation id="jimd12146-cit-0057" publication-type="book">
<string-name>
<surname>Brusilow</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Horwich</surname>
<given-names>AL</given-names>
</string-name>. <chapter-title>Urea cycle enzymes</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Scriver</surname><given-names>CRBAL</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Sly</surname><given-names>WS</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Valle</surname><given-names>D</given-names></name></person-group>, eds. <source xml:lang="en"/>The Metabolic and Molecular Bases of Inherited Disease. <edition designator="8">8th ed.</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>McGraw‐Hill</publisher-name>; <year>2001</year>.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0058">
<label>58</label>
<mixed-citation id="jimd12146-cit-0058" publication-type="book">
<string-name>
<surname>Quinonez</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Thoene</surname>
<given-names>JG</given-names>
</string-name> (<year>1993</year>) <chapter-title>Citrullinemia type I. 2004 Jul 7 [updated 2016 Sep 1]</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Ardinger</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name></person-group>, et al., editors. <source xml:lang="en"/>GeneReviews® [Internet]. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; 1993–2019. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1458/">https://www.ncbi.nlm.nih.gov/books/NBK1458/</ext-link>
</mixed-citation>
</ref>
<ref id="jimd12146-bib-0059">
<label>59</label>
<mixed-citation id="jimd12146-cit-0059" publication-type="journal">
<string-name>
<surname>Gunz</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Choong</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Potter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>E</given-names>
</string-name>. <article-title>Magnetic resonance imaging findings and neurodevelopmental outcomes in neonates with urea‐cycle defects</article-title>. <source xml:lang="en"/>Int Med Case Rep J. <year>2013</year>;<volume>6</volume>:<fpage>41</fpage>‐<lpage>48</lpage>.<pub-id pub-id-type="pmid">23983495</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0060">
<label>60</label>
<mixed-citation id="jimd12146-cit-0060" publication-type="journal">
<string-name>
<surname>Faghfoury</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Baruteau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>de Baulny</surname>
<given-names>HO</given-names>
</string-name>, <string-name>
<surname>Haberle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schulze</surname>
<given-names>A</given-names>
</string-name>. <article-title>Transient fulminant liver failure as an initial presentation in citrullinemia type I</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2011</year>;<volume>102</volume>:<fpage>413</fpage>‐<lpage>417</lpage>.<pub-id pub-id-type="pmid">21227727</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0061">
<label>61</label>
<mixed-citation id="jimd12146-cit-0061" publication-type="journal">
<string-name>
<surname>De Bie</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lemyre</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lambert</surname>
<given-names>M</given-names>
</string-name>. <article-title>Favorable long‐term outcome following severe neonatal Hyperammonemic coma in a patient with argininosuccinate synthetase deficiency</article-title>. <source xml:lang="en"/>JIMD Reports. <year>2011</year>;<volume>1</volume>:<fpage>83</fpage>‐<lpage>88</lpage>.<pub-id pub-id-type="pmid">23430833</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0062">
<label>62</label>
<mixed-citation id="jimd12146-cit-0062" publication-type="journal">
<string-name>
<surname>Glamuzina</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Marquis‐Nicholson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Knoll</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Love</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>C</given-names>
</string-name>. <article-title>Citrullinaemia type I: a common mutation in the Pacific Island population</article-title>. <source xml:lang="en"/>J Paediatr Child Health. <year>2011</year>;<volume>47</volume>:<fpage>262</fpage>‐<lpage>265</lpage>.<pub-id pub-id-type="pmid">21244552</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0063">
<label>63</label>
<mixed-citation id="jimd12146-cit-0063" publication-type="journal">
<string-name>
<surname>Karall</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Haberlandt</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Albrecht</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Rostasy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Haberle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Scholl‐Burgi</surname>
<given-names>S</given-names>
</string-name>. <article-title>Unrecognized citrullinemia mimicking encephalitis in a 14‐year‐old boy: unexpected result through the use of a standardized lumbar puncture protocol</article-title>. <source xml:lang="en"/>Neuropediatrics. <year>2012</year>;<volume>43</volume>:<fpage>59</fpage>‐<lpage>63</lpage>.<pub-id pub-id-type="pmid">22473243</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0064">
<label>64</label>
<mixed-citation id="jimd12146-cit-0064" publication-type="journal">
<string-name>
<surname>Brunetti‐Pierri</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lamance</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Craigen</surname>
<given-names>WJ</given-names>
</string-name>. <article-title>30‐year follow‐up of a patient with classic citrullinemia</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2012</year>;<volume>106</volume>:<fpage>248</fpage>‐<lpage>250</lpage>.<pub-id pub-id-type="pmid">22494546</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0065">
<label>65</label>
<mixed-citation id="jimd12146-cit-0065" publication-type="journal">
<string-name>
<surname>Waisbren</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Cuthbertson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Burgard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Holbert</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McCarter</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cederbaum</surname>
<given-names>S</given-names>
</string-name>. <article-title>Biochemical markers and neuropsychological functioning in distal urea cycle disorders</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2018</year>;<volume>41</volume>:<fpage>657</fpage>‐<lpage>667</lpage>.<pub-id pub-id-type="pmid">29423830</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0066">
<label>66</label>
<mixed-citation id="jimd12146-cit-0066" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Heo</surname>
<given-names>SH</given-names>
</string-name>, et al. <article-title>High prevalence of neonatal presentation in Korean patients with citrullinemia type 1, and their shared mutations</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2013</year>;<volume>108</volume>:<fpage>18</fpage>‐<lpage>24</lpage>.<pub-id pub-id-type="pmid">23246278</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0067">
<label>67</label>
<mixed-citation id="jimd12146-cit-0067" publication-type="journal">
<string-name>
<surname>Ficicioglu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mandell</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Shih</surname>
<given-names>VE</given-names>
</string-name>. <article-title>Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2009</year>;<volume>98</volume>:<fpage>273</fpage>‐<lpage>277</lpage>.<pub-id pub-id-type="pmid">19635676</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0068">
<label>68</label>
<mixed-citation id="jimd12146-cit-0068" publication-type="journal">
<string-name>
<surname>Mercimek‐Mahmutoglu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Moeslinger</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Haberle</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Long‐term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2010</year>;<volume>100</volume>:<fpage>24</fpage>‐<lpage>28</lpage>.<pub-id pub-id-type="pmid">20236848</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0069">
<label>69</label>
<mixed-citation id="jimd12146-cit-0069" publication-type="journal">
<string-name>
<surname>Kolker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Valayannopoulos</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Burlina</surname>
<given-names>AB</given-names>
</string-name>, et al. <article-title>The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2015</year>;<volume>38</volume>:<fpage>1059</fpage>‐<lpage>1074</lpage>.<pub-id pub-id-type="pmid">25875216</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0070">
<label>70</label>
<mixed-citation id="jimd12146-cit-0070" publication-type="book">
<string-name>
<surname>Nagamani</surname>
<given-names>SCS</given-names>
</string-name>, <string-name>
<surname>Erez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>B</given-names>
</string-name> (<year>1993</year>) <chapter-title>Argininosuccinate Lyase deficiency. 2011 Feb 3 [updated 2019 mar 28]</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Ardinger</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name></person-group>, et al., editors. <source xml:lang="en"/>GeneReviews® [Internet]. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; 1993‐2019. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK51784/">https://www.ncbi.nlm.nih.gov/books/NBK51784/</ext-link>
</mixed-citation>
</ref>
<ref id="jimd12146-bib-0071">
<label>71</label>
<mixed-citation id="jimd12146-cit-0071" publication-type="journal">
<string-name>
<surname>Burgard</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kolker</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haege</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lindner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>
<given-names>GF</given-names>
</string-name>. <article-title>Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders‐‐review and meta‐analysis of observational studies published over more than 35 years</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2016</year>;<volume>39</volume>:<fpage>219</fpage>‐<lpage>229</lpage>.<pub-id pub-id-type="pmid">26634836</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0072">
<label>72</label>
<mixed-citation id="jimd12146-cit-0072" publication-type="journal">
<string-name>
<surname>Barends</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pitt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Morrissy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tzanakos</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Boneh</surname>
<given-names>A</given-names>
</string-name>. <article-title>Biochemical and molecular characteristics of patients with organic acidaemias and urea cycle disorders identified through newborn screening</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2014</year>;<volume>113</volume>:<fpage>46</fpage>‐<lpage>52</lpage>.<pub-id pub-id-type="pmid">25047749</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0073">
<label>73</label>
<mixed-citation id="jimd12146-cit-0073" publication-type="journal">
<string-name>
<surname>Yankol</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mecit</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kanmaz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Acarli</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kalayoglu</surname>
<given-names>M</given-names>
</string-name>. <article-title>Argininosuccinic Aciduria‐a rare indication for liver transplant: report of two cases</article-title>. <source xml:lang="en"/>Exp Clin Transplant. <year>2017</year>;<volume>15</volume>:<fpage>581</fpage>‐<lpage>584</lpage>.<pub-id pub-id-type="pmid">26768012</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0074">
<label>74</label>
<mixed-citation id="jimd12146-cit-0074" publication-type="journal">
<string-name>
<surname>Keskinen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Siitonen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Salo</surname>
<given-names>M</given-names>
</string-name>. <article-title>Hereditary urea cycle diseases in Finland</article-title>. <source xml:lang="en"/>Acta Paediatr. <year>2008</year>;<volume>97</volume>:<fpage>1412</fpage>‐<lpage>1419</lpage>.<pub-id pub-id-type="pmid">18616627</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0075">
<label>75</label>
<mixed-citation id="jimd12146-cit-0075" publication-type="journal">
<string-name>
<surname>Tuchman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lichter‐Konecki</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Cross‐sectional multicenter study of patients with urea cycle disorders in the United States</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2008</year>;<volume>94</volume>:<fpage>397</fpage>‐<lpage>402</lpage>.<pub-id pub-id-type="pmid">18562231</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0076">
<label>76</label>
<mixed-citation id="jimd12146-cit-0076" publication-type="journal">
<string-name>
<surname>Ganetzky</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Bedoukian</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Deardorff</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Ficicioglu</surname>
<given-names>C</given-names>
</string-name>. <article-title>Argininosuccinic acid lyase deficiency missed by newborn screen</article-title>. <source xml:lang="en"/>JIMD Rep. <year>2017</year>;<volume>34</volume>:<fpage>43</fpage>‐<lpage>47</lpage>.<pub-id pub-id-type="pmid">27515243</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0077">
<label>77</label>
<mixed-citation id="jimd12146-cit-0077" publication-type="journal">
<string-name>
<surname>Grioni</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Furlan</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Corbetta</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Epilepsy and argininosuccinic aciduria</article-title>. <source xml:lang="en"/>Neuropediatrics. <year>2011</year>;<volume>42</volume>:<fpage>97</fpage>‐<lpage>103</lpage>.<pub-id pub-id-type="pmid">21744316</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0078">
<label>78</label>
<mixed-citation id="jimd12146-cit-0078" publication-type="journal">
<string-name>
<surname>Baruteau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jameson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>AA</given-names>
</string-name>, et al. <article-title>Expanding the phenotype in argininosuccinic aciduria: need for new therapies</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2017</year>;<volume>40</volume>:<fpage>357</fpage>‐<lpage>368</lpage>.<pub-id pub-id-type="pmid">28251416</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0079">
<label>79</label>
<mixed-citation id="jimd12146-cit-0079" publication-type="journal">
<string-name>
<surname>Sin</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Baron</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schulze</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Funk</surname>
<given-names>CD</given-names>
</string-name>. <article-title>Arginase‐1 deficiency</article-title>. <source xml:lang="en"/>J Mol Med (Berl). <year>2015</year>;<volume>93</volume>:<fpage>1287</fpage>‐<lpage>1296</lpage>.<pub-id pub-id-type="pmid">26467175</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0080">
<label>80</label>
<mixed-citation id="jimd12146-cit-0080" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>HY</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Yoo</surname>
<given-names>HW</given-names>
</string-name>. <article-title>Argininemia presenting with progressive spastic diplegia</article-title>. <source xml:lang="en"/>Pediatr Neurol. <year>2011</year>;<volume>44</volume>:<fpage>218</fpage>‐<lpage>220</lpage>.<pub-id pub-id-type="pmid">21310339</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0081">
<label>81</label>
<mixed-citation id="jimd12146-cit-0081" publication-type="journal">
<string-name>
<surname>Cederbaum</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Moedjono</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Naylor</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Walzer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Treatment of hyperargininaemia due to arginase deficiency with a chemically defined diet</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1982</year>;<volume>5</volume>:<fpage>95</fpage>‐<lpage>99</lpage>.<pub-id pub-id-type="pmid">6820432</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0082">
<label>82</label>
<mixed-citation id="jimd12146-cit-0082" publication-type="journal">
<string-name>
<surname>Scaglia</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>B</given-names>
</string-name>. <article-title>Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency</article-title>. <source xml:lang="en"/>Am J Med Genet C Semin Med Genet. <year>2006</year>;<volume>142c</volume>:<fpage>113</fpage>‐<lpage>120</lpage>.<pub-id pub-id-type="pmid">16602094</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0083">
<label>83</label>
<mixed-citation id="jimd12146-cit-0083" publication-type="journal">
<string-name>
<surname>Silva</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Cardoso</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Vilarinho</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Medina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barbot</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Martins</surname>
<given-names>E</given-names>
</string-name>. <article-title>Liver transplantation prevents progressive neurological impairment in argininemia</article-title>. <source xml:lang="en"/>JIMD Rep. <year>2013</year>;<volume>11</volume>:<fpage>25</fpage>‐<lpage>30</lpage>.<pub-id pub-id-type="pmid">23559324</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0084">
<label>84</label>
<mixed-citation id="jimd12146-cit-0084" publication-type="journal">
<string-name>
<surname>Görker</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tüzün</surname>
<given-names>Ü</given-names>
</string-name>. <article-title>Autistic‐like findings associated with a urea cycle disorder in a 4‐year‐old girl</article-title>. <source xml:lang="en"/>J Psychiatry Neurosci. <year>2005</year>;<volume>30</volume>:<fpage>133</fpage>‐<lpage>135</lpage>.<pub-id pub-id-type="pmid">15798789</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0085">
<label>85</label>
<mixed-citation id="jimd12146-cit-0085" publication-type="journal">
<string-name>
<surname>Baranello</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Alfei</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Martinelli</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Hyperargininemia: 7‐month follow‐up under sodium benzoate therapy in an Italian child presenting progressive spastic paraparesis, cognitive decline, and novel mutation in ARG1 gene</article-title>. <source xml:lang="en"/>Pediatr Neurol. <year>2014</year>;<volume>51</volume>:<fpage>430</fpage>‐<lpage>433</lpage>.<pub-id pub-id-type="pmid">24997092</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0086">
<label>86</label>
<mixed-citation id="jimd12146-cit-0086" publication-type="book">
<string-name>
<surname>Saheki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>YZ</given-names>
</string-name> (<year>1993</year>) <chapter-title>Citrin deficiency. 2005 Sep 16 [updated 2017 Aug 10]</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Ardinger</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name></person-group>, et al., editors. <source xml:lang="en"/>GeneReviews® [Internet]. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; 1993–2019. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1181/">https://www.ncbi.nlm.nih.gov/books/NBK1181/</ext-link>
</mixed-citation>
</ref>
<ref id="jimd12146-bib-0087">
<label>87</label>
<mixed-citation id="jimd12146-cit-0087" publication-type="journal">
<string-name>
<surname>Hutchin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Preece</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Hendriksz</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) as a cause of liver disease in infants in the UK</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2009</year>;<volume>32</volume>(<issue>Suppl 1</issue>):<fpage>S151</fpage>‐<lpage>S155</lpage>.<pub-id pub-id-type="pmid">19517266</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0088">
<label>88</label>
<mixed-citation id="jimd12146-cit-0088" publication-type="journal">
<string-name>
<surname>Dimmock</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Maranda</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dionisi‐Vici</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Citrin deficiency, a perplexing global disorder</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2009</year>;<volume>96</volume>:<fpage>44</fpage>‐<lpage>49</lpage>.<pub-id pub-id-type="pmid">19036621</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0089">
<label>89</label>
<mixed-citation id="jimd12146-cit-0089" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Chien</surname>
<given-names>YH</given-names>
</string-name>, et al. <article-title>Tandem mass neonatal screening in Taiwan‐‐report from one center</article-title>. <source xml:lang="en"/>J Formos Med Assoc. <year>2006</year>;<volume>105</volume>:<fpage>882</fpage>‐<lpage>886</lpage>.<pub-id pub-id-type="pmid">17098689</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0090">
<label>90</label>
<mixed-citation id="jimd12146-cit-0090" publication-type="journal">
<string-name>
<surname>Shigetomi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nagao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsutsumi</surname>
<given-names>H</given-names>
</string-name>. <article-title>Early detection and diagnosis of neonatal intrahepatic cholestasis caused by Citrin deficiency missed by Newborn screening using tandem mass spectrometry</article-title>. <source xml:lang="en"/>Int J Neonatal Screen. <year>2018</year>;<volume>4</volume>:<fpage>5</fpage>.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0091">
<label>91</label>
<mixed-citation id="jimd12146-cit-0091" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Ni</surname>
<given-names>YH</given-names>
</string-name>, et al. <article-title>Chubby face and the biochemical parameters for the early diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency</article-title>. <source xml:lang="en"/>J Pediatr Gastroenterol Nutr. <year>2008</year>;<volume>47</volume>:<fpage>187</fpage>‐<lpage>192</lpage>.<pub-id pub-id-type="pmid">18664871</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0092">
<label>92</label>
<mixed-citation id="jimd12146-cit-0092" publication-type="journal">
<string-name>
<surname>Song</surname>
<given-names>YZ</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>FP</given-names>
</string-name>, et al. <article-title>Genotypic and phenotypic features of citrin deficiency: five‐year experience in a Chinese pediatric center</article-title>. <source xml:lang="en"/>Int J Mol Med. <year>2011</year>;<volume>28</volume>:<fpage>33</fpage>‐<lpage>40</lpage>.<pub-id pub-id-type="pmid">21424115</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0093">
<label>93</label>
<mixed-citation id="jimd12146-cit-0093" publication-type="journal">
<string-name>
<surname>Guo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>B‐X</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Etiological analysis of neurodevelopmental disabilities: single‐Center eight‐year clinical experience in South China</article-title>. <source xml:lang="en"/>J Biomed Biotechnol. <year>2011</year>;<volume>2011</volume>:<fpage>11</fpage>.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0094">
<label>94</label>
<mixed-citation id="jimd12146-cit-0094" publication-type="journal">
<string-name>
<surname>Hayasaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Numakura</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Yamakawa</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Medium‐chain triglycerides supplement therapy with a low‐carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult‐onset type II citrullinemia</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2018</year>;<volume>41</volume>:<fpage>777</fpage>‐<lpage>784</lpage>.<pub-id pub-id-type="pmid">29651749</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0095">
<label>95</label>
<mixed-citation id="jimd12146-cit-0095" publication-type="journal">
<string-name>
<surname>Mutoh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kurokawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Saheki</surname>
<given-names>T</given-names>
</string-name>. <article-title>Treatment of a citrin‐deficient patient at the early stage of adult‐onset type II citrullinaemia with arginine and sodium pyruvate</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2008</year>;<volume>31</volume>(<issue>Suppl 2</issue>):<fpage>S343</fpage>‐<lpage>S347</lpage>.<pub-id pub-id-type="pmid">18958581</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0096">
<label>96</label>
<mixed-citation id="jimd12146-cit-0096" publication-type="journal">
<string-name>
<surname>Saheki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tushima</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mutoh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</string-name>. <article-title>Citrin deficiency and current treatment concepts</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2010</year>;<volume>100</volume>(<issue>suppl 1</issue>):<fpage>S59</fpage>‐<lpage>S64</lpage>.<pub-id pub-id-type="pmid">20233664</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0097">
<label>97</label>
<mixed-citation id="jimd12146-cit-0097" publication-type="journal">
<string-name>
<surname>Kyo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mii</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takekita</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Case of adult‐onset type II citrullinemia treated as schizophrenia for a long time</article-title>. <source xml:lang="en"/>Psychiatry Clin Neurosci. <year>2015</year>;<volume>69</volume>:<fpage>306</fpage>‐<lpage>307</lpage>.<pub-id pub-id-type="pmid">25384800</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0098">
<label>98</label>
<mixed-citation id="jimd12146-cit-0098" publication-type="journal">
<string-name>
<surname>Choi</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jo</surname>
<given-names>YY</given-names>
</string-name>. <article-title>Anesthetic experience of an adult male with citrullinemia type II: a case report</article-title>. <source xml:lang="en"/>BMC Anesthesiol. <year>2016</year>;<volume>16</volume>:<fpage>92</fpage>.<pub-id pub-id-type="pmid">27724842</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0099">
<label>99</label>
<mixed-citation id="jimd12146-cit-0099" publication-type="journal">
<string-name>
<surname>Komine</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Minamimura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Sudden development of adult‐onset type II citrullinemia after total gastrectomy: a case report</article-title>. <source xml:lang="en"/>Surg Case Rep. <year>2018</year>;<volume>4</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">29368097</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0100">
<label>100</label>
<mixed-citation id="jimd12146-cit-0100" publication-type="journal">
<string-name>
<surname>Tonini</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Bignamini</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mattioli</surname>
<given-names>M</given-names>
</string-name>. <article-title>Headache and neuropsychic disorders in the puerperium: a case report with suspected deficiency of urea cycle enzymes</article-title>. <source xml:lang="en"/>Neurol Sci. <year>2011</year>;<volume>32</volume>:<fpage>157</fpage>‐<lpage>159</lpage>.</mixed-citation>
</ref>
<ref id="jimd12146-bib-0101">
<label>101</label>
<mixed-citation id="jimd12146-cit-0101" publication-type="journal">
<string-name>
<surname>Saheki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakano</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Analysis of the enzyme abnormality in eight cases of neonatal and infantile citrullinaemia in Japan</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>1985</year>;<volume>8</volume>:<fpage>155</fpage>‐<lpage>156</lpage>.<pub-id pub-id-type="pmid">3939592</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0102">
<label>102</label>
<mixed-citation id="jimd12146-cit-0102" publication-type="journal">
<string-name>
<surname>Saheki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hosoya</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Qualitative and quantitative abnormalities of argininosuccinate synthetase in citrullinemia</article-title>. <source xml:lang="en"/>Clinica Chimica Acta; International Journal of Clinical Chemistry. <year>1981</year>;<volume>109</volume>:<fpage>325</fpage>‐<lpage>335</lpage>.<pub-id pub-id-type="pmid">6784969</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0103">
<label>103</label>
<mixed-citation id="jimd12146-cit-0103" publication-type="journal">
<string-name>
<surname>Martinelli</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Diodato</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ponzi</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The hyperornithinemia‐hyperammonemia‐homocitrullinuria syndrome</article-title>. <source xml:lang="en"/>Orphanet J Rare Dis. <year>2015</year>;<volume>10</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">25874378</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0104">
<label>104</label>
<mixed-citation id="jimd12146-cit-0104" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>SZ</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Nyhan</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Ficicioglu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mandell</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Shih</surname>
<given-names>VE</given-names>
</string-name>. <article-title>Long‐term follow‐up of four patients affected by HHH syndrome</article-title>. <source xml:lang="en"/>Clin Chim Acta. <year>2012</year>;<volume>413</volume>:<fpage>1151</fpage>‐<lpage>1155</lpage>.<pub-id pub-id-type="pmid">22465082</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0105">
<label>105</label>
<mixed-citation id="jimd12146-cit-0105" publication-type="journal">
<string-name>
<surname>Guan</surname>
<given-names>HZ</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>DX</given-names>
</string-name>, et al. <article-title>Clinical diagnosis and treatment of three cases with hyperornithinemia‐hyperammonemia‐homocitrullinuria syndrome</article-title>. <source xml:lang="en"/>Zhonghua Er Ke Za Zhi. <year>2017</year>;<volume>55</volume>:<fpage>428</fpage>‐<lpage>433</lpage>.<pub-id pub-id-type="pmid">28592010</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0106">
<label>106</label>
<mixed-citation id="jimd12146-cit-0106" publication-type="journal">
<string-name>
<surname>Seminara</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tuchman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Krivitzky</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Establishing a consortium for the study of rare diseases: the urea cycle disorders consortium</article-title>. <source xml:lang="en"/>Mol Genet Metab. <year>2010</year>;<volume>100</volume>(<issue>Suppl 1</issue>):<fpage>S97</fpage>‐<lpage>S105</lpage>.<pub-id pub-id-type="pmid">20188616</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0107">
<label>107</label>
<mixed-citation id="jimd12146-cit-0107" publication-type="journal">
<string-name>
<surname>Gropman</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Summar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>JV</given-names>
</string-name>. <article-title>Neurological implications of urea cycle disorders</article-title>. <source xml:lang="en"/>J Inherit Metab Dis. <year>2007</year>;<volume>30</volume>:<fpage>865</fpage>‐<lpage>879</lpage>.<pub-id pub-id-type="pmid">18038189</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0108">
<label>108</label>
<mixed-citation id="jimd12146-cit-0108" publication-type="journal">
<string-name>
<surname>Caldovic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Abdikarim</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Narain</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tuchman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morizono</surname>
<given-names>H</given-names>
</string-name>. <article-title>Genotype‐phenotype correlations in ornithine transcarbamylase deficiency: a mutation update</article-title>. <source xml:lang="en"/>J Genet Genomics. <year>2015</year>;<volume>42</volume>:<fpage>181</fpage>‐<lpage>194</lpage>.<pub-id pub-id-type="pmid">26059767</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0109">
<label>109</label>
<mixed-citation id="jimd12146-cit-0109" publication-type="journal">
<string-name>
<surname>Debray</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Lambert</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lemieux</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Phenotypic variability among patients with hyperornithinaemia‐hyperammonaemia‐homocitrullinuria syndrome homozygous for the delF188 mutation in SLC25A15</article-title>. <source xml:lang="en"/>J Med Genet. <year>2008</year>;<volume>45</volume>:<fpage>759</fpage>‐<lpage>764</lpage>.<pub-id pub-id-type="pmid">18978333</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0110">
<label>110</label>
<mixed-citation id="jimd12146-cit-0110" publication-type="journal">
<string-name>
<surname>Diaz</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Krivitzky</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Mokhtarani</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate</article-title>. <source xml:lang="en"/>Hepatology. <year>2013</year>;<volume>57</volume>:<fpage>2171</fpage>‐<lpage>2179</lpage>.<pub-id pub-id-type="pmid">22961727</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0111">
<label>111</label>
<mixed-citation id="jimd12146-cit-0111" publication-type="journal">
<string-name>
<surname>Glavind</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Aagaard</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Grønbæk</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Alcoholic hepatitis markedly decreases the capacity for urea synthesis</article-title>. <source xml:lang="en"/>PLOS One. <year>2016</year>;<volume>11</volume>:<elocation-id>e0158388</elocation-id>.<pub-id pub-id-type="pmid">27379798</pub-id></mixed-citation>
</ref>
<ref id="jimd12146-bib-0112">
<label>112</label>
<mixed-citation id="jimd12146-cit-0112" publication-type="journal">
<string-name>
<surname>Buerger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Garbade</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Dietrich</surname>
<given-names>AF</given-names>
</string-name>, et al. <article-title>Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain‐specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events</article-title>. <source xml:lang="en"/>J Inherited Metab Dis. <year>2019</year>;<volume>42</volume>:<fpage>243</fpage>‐<lpage>253</lpage>.<pub-id pub-id-type="pmid">30671983</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>